Eric Small, MD

Title(s)Professor, Medicine
SchoolSchool of Medicine
Phone415-353-7095
Emaileric.small@ucsf.edu
ORCID ORCID Icon0000-0003-3191-6268 Additional info
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    Stanford University, Stanford, CAB.S.1980Biology
    Case Western Reserve University, Cleveland, OHStudent Fellowship1983Pathology Residency Training Program
    Case Western Reserve University, Cleveland, OHM.D.1985Medicine
    Beth Israel Hospital, Boston, MAInternship1986Internal Medicine
    Beth Israel Hospital, Boston, MAResidency1988Internal Medicine
    University of California, San Francisco, San Francisco, CAPost-Doc Fellow/Scholar1991 Medicine (Cancer Research Institute)
    Collapse Awards and Honors
     - 1984Alpha Omega Alpha Honor Medical Society
     - 2001 UCSF Division of Hematology-Oncology: Faculty Research Award
     - 2011Richard L. Schilsky CALGB Award for Clinical Research
     - 2011UCSF Academic Senate Faculty Research Lecture in Clinical Science
     - 2015Fellow of the American Society of Clinical Oncology (FASCO)

    Collapse Overview 
    Collapse Overview
    My interests lie in clinical and translational research in advanced prostate cancer, including trial design, and development of novel agents. I piloted the early trials targeting the androgen receptor in advanced prostate cancer, developing ketoconazole and contributing to an understanding of its mechanisms of activity and resistance. I subsequently was centrally involved with the development of two novel androgen signaling inhibitors, abiraterone acetate and apalutamide, from first in human studies to FDA approval.

    I have also been involved in the early application of immunotherapy to prostate cancer, developing sipuleucel T from first in human studies through FDA approval, and undertaking the first in human testing of ipilimumab, the first immune check point inhibitor to be clinically developed.

    Understanding the mechanisms of resistance in advanced prostate cancer has been a research focus. I was principal investigator of a $10 million multi-center Stand Up to Cancer (SU2C)/Prostate Cancer Foundation Dream Team Award undertaking deep genomic characterization of prostate cancer metastases, in order to elucidate patterns of resistance in abiraterone and/or enzalutamide
    treated patients. Important observations from this, and subsequent work have included unexpectedly high prevalence rates of treatment associated small cell/neuroendocrine prostate cancer (t-SCNC), as well as key structural variants which contribute to progression of castration-resistant disease.

    I hold a number of leadership roles, serving as Co-Leader of the UCSF Prostate Cancer Program, and as Deputy Director of the UCSF Helen Diller Family Comprehensive Cancer Center. I previously served as Chief of the Division of Hematology and Oncology in the UCSF Department of Medicine for 10 years, and most recently have assumed the position of Chief Scientific Officer in the UCSF Helen Diller Family Comprehensive Cancer Center. Nationally, I serve on the ASCO Board of Directors, and chair of 4 External Advisory Boards for other NCI Designated Cancer Centers.

    Collapse ORNG Applications 
    Collapse Academic Senate

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Prostate-specific Membrane Antigen Positron Emission Tomography-detected Disease Extent and Overall Survival of Patients with High-risk Nonmetastatic Castration-resistant Prostate Cancer: An International Multicenter Retrospective Study. Eur Urol. 2024 Mar 14. Weber M, Fendler WP, Ravi Kumar AS, Calais J, Czernin J, Ilhan H, Saad F, Kretschmer A, Hekimsoy T, Brookman-May SD, Mundle SD, Small EJ, Smith MR, Perez PM, Hope TA, Herrmann K, Hofman MS, Eiber M, Hadaschik BA. PMID: 38490855.
      View in: PubMed   Mentions:    Fields:    
    2. Pharmacogenetic and clinical risk factors for bevacizumab-related gastrointestinal hemorrhage in prostate cancer patients treated on CALGB 90401 (Alliance). Pharmacogenomics J. 2024 Mar 04; 24(2):6. Patel JN, Jiang C, Owzar K, Hertz DL, Wang J, Mulkey FA, Kelly WK, Halabi S, Furukawa Y, Lassiter C, Dorsey SG, Friedman PN, Small EJ, Carducci MA, Kelley MJ, Nakamura Y, Kubo M, Ratain MJ, Morris MJ, McLeod HL. PMID: 38438359; PMCID: PMC10912014.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    3. Immune modulation with RANKL blockade through denosumab treatment in patients with cancer. Cancer Immunol Res. 2024 Jan 26. Chang H, Marquez Garcia J, Chen BK, Kim DM, Cheng ML, Liu EV, Yang H, Zhang L, Sinha M, Cheung A, Kwek SS, Chow ED, Bridge M, Aggarwal RR, Friedlander TW, Small EJ, Anderson M, Fong L. PMID: 38276989.
      View in: PubMed   Mentions:    Fields:    
    4. Post Hoc Analysis of Rapid and Deep Prostate-specific Antigen Decline and Patient-reported Health-related Quality of Life in SPARTAN and TITAN Patients with Advanced Prostate Cancer. Eur Urol Oncol. 2023 Dec 09. Small EJ, Chi KN, Chowdhury S, Bevans KB, Bhaumik A, Saad F, Chung BH, Karsh LI, Oudard S, De Porre P, Brookman-May SD, McCarthy SA, Mundle SD, Uemura H, Smith MR, Agarwal N. PMID: 38072759.
      View in: PubMed   Mentions:    Fields:    
    5. Correction to: Clinical characteristics associated with falls in patients with non-metastatic castration-resistant prostate cancer treated with apalutamide. Prostate Cancer Prostatic Dis. 2023 Dec; 26(4):813. Pollock Y, Smith MR, Saad F, Chowdhury S, Oudard S, Hadaschik B, Olmos D, Lee JY, Uemura H, Bhaumik A, Londhe A, Rooney B, Brookman-May SD, De Porre P, Mundle SD, Small EJ. PMID: 37620428.
      View in: PubMed   Mentions:    Fields:    
    6. Cancer Research in 2030: A unique strategic planning process at a comprehensive cancer center. Prev Oncol Epidemiol. 2023; 1(1):1-9. Bank EM, Small EJ, Ashworth A, Hiatt RA. PMID: 38525348; PMCID: PMC10959521.
      View in: PubMed   Mentions:
    7. Apalutamide efficacy, safety and wellbeing in older patients with advanced prostate cancer from Phase 3 randomised clinical studies TITAN and SPARTAN. Br J Cancer. 2024 01; 130(1):73-81. Shen J, Chowdhury S, Agarwal N, Karsh LI, Oudard S, Gartrell BA, Feyerabend S, Saad F, Pieczonka CM, Chi KN, Brookman-May SD, Rooney B, Bhaumik A, McCarthy SA, Bevans KB, Mundle SD, Small EJ, Smith MR, Graff JN. PMID: 37951974; PMCID: PMC10781967.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    8. Single-dose 177Lu-PSMA-617 followed by maintenance pembrolizumab in patients with metastatic castration-resistant prostate cancer: an open-label, dose-expansion, phase 1 trial. Lancet Oncol. 2023 Nov; 24(11):1266-1276. Aggarwal R, Starzinski S, de Kouchkovsky I, Koshkin V, Bose R, Chou J, Desai A, Kwon D, Kaushal S, Trihy L, Rastogi M, Ippisch R, Aslam M, Friedlander T, Feng F, Oh D, Cheung A, Small E, Evans M, Fong L, Hope TA. PMID: 37922930; PMCID: PMC10667020.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    9. The Genomic and Epigenomic Landscape of Double-Negative Metastatic Prostate Cancer. Cancer Res. 2023 08 15; 83(16):2763-2774. Lundberg A, Zhang M, Aggarwal R, Li H, Zhang L, Foye A, Sjöström M, Chou J, Chang K, Moreno-Rodriguez T, Shrestha R, Baskin A, Zhu X, Weinstein AS, Younger N, Alumkal JJ, Beer TM, Chi KN, Evans CP, Gleave M, Lara PN, Reiter RE, Rettig MB, Witte ON, Wyatt AW, Feng FY, Small EJ, Quigley DA. PMID: 37289025; PMCID: PMC10425725.
      View in: PubMed   Mentions: 6     Fields:    
    10. Flashback Foreword: Gemcitabine/Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Transitional Cell Carcinoma. J Clin Oncol. 2023 08 10; 41(23):3879-3880. Small EJ. PMID: 37549481.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    11. Impact of Squamous Histology on Clinical Outcomes and Molecular Profiling in Metastatic Urothelial Carcinoma Patients Treated With Immune Checkpoint Inhibitors or Enfortumab Vedotin. Clin Genitourin Cancer. 2023 10; 21(5):e394-e404. Jindal T, Zhang L, Deshmukh P, Reyes K, Chan E, Kumar V, Zhu X, Maldonado E, Feng S, Johnson M, Angelidakis A, Kwon D, Desai A, Borno HT, Bose R, Wong A, Hong J, Carroll P, Meng M, Porten S, Aggarwal R, Small EJ, Fong L, Chou J, Friedlander T, de Kouchkovsky I, Koshkin VS. PMID: 37316414.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    12. External Validation of a Prognostic Model of Overall Survival in Men With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer. J Clin Oncol. 2023 05 20; 41(15):2736-2746. Halabi S, Yang Q, Roy A, Luo B, Araujo JC, Logothetis C, Sternberg CN, Armstrong AJ, Carducci MA, Chi KN, de Bono JS, Petrylak DP, Fizazi K, Higano CS, Morris MJ, Rathkopf DE, Saad F, Ryan CJ, Small EJ, Kelly WK. PMID: 37040594; PMCID: PMC10414709.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    13. Somatic alterations of TP53 and MDM2 associated with response to enfortumab vedotin in patients with advanced urothelial cancer. Front Oncol. 2023; 13:1161089. Jindal T, Zhu X, Bose R, Kumar V, Maldonado E, Deshmukh P, Shipp C, Feng S, Johnson MS, Angelidakis A, Kwon D, Borno HT, de Kouchkovsky I, Desai A, Aggarwal R, Fong L, Small EJ, Wong A, Porten S, Chou J, Friedlander T, Koshkin VS. PMID: 37091148; PMCID: PMC10113661.
      View in: PubMed   Mentions:
    14. Randomized Phase III Study of Enzalutamide Compared With Enzalutamide Plus Abiraterone for Metastatic Castration-Resistant Prostate Cancer (Alliance A031201 Trial). J Clin Oncol. 2023 06 20; 41(18):3352-3362. Morris MJ, Heller G, Hillman DW, Bobek O, Ryan C, Antonarakis ES, Bryce AH, Hahn O, Beltran H, Armstrong AJ, Schwartz L, Lewis LD, Beumer JH, Langevin B, McGary EC, Mehan PT, Goldkorn A, Roth BJ, Xiao H, Watt C, Taplin ME, Halabi S, Small EJ. PMID: 36996380; PMCID: PMC10414728.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCTClinical Trials
    15. Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer. J Clin Oncol. 2023 06 20; 41(18):3339-3351. Chi KN, Rathkopf D, Smith MR, Efstathiou E, Attard G, Olmos D, Lee JY, Small EJ, Pereira de Santana Gomes AJ, Roubaud G, Saad M, Zurawski B, Sakalo V, Mason GE, Francis P, Wang G, Wu D, Diorio B, Lopez-Gitlitz A, Sandhu S, MAGNITUDE Principal Investigators. PMID: 36952634; PMCID: PMC10431499.
      View in: PubMed   Mentions: 31     Fields:    Translation:HumansCTClinical Trials
    16. Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022. Eur J Cancer. 2023 05; 185:178-215. Gillessen S, Bossi A, Davis ID, de Bono J, Fizazi K, James ND, Mottet N, Shore N, Small E, Smith M, Sweeney CJ, Tombal B, Antonarakis ES, Aparicio AM, Armstrong AJ, Attard G, Beer TM, Beltran H, Bjartell A, Blanchard P, Briganti A, Bristow RG, Bulbul M, Caffo O, Castellano D, Castro E, Cheng HH, Chi KN, Chowdhury S, Clarke CS, Clarke N, Daugaard G, De Santis M, Duran I, Eeles R, Efstathiou E, Efstathiou J, Ekeke ON, Evans CP, Fanti S, Feng FY, Fonteyne V, Fossati N, Frydenberg M, George D, Gleave M, Gravis G, Halabi S, Heinrich D, Herrmann K, Higano C, Hofman MS, Horvath LG, Hussain M, Jereczek-Fossa BA, Jones R, Kanesvaran R, Kellokumpu-Lehtinen PL, Khauli RB, Klotz L, Kramer G, Leibowitz R, Logothetis C, Mahal B, Maluf F, Mateo J, Matheson D, Mehra N, Merseburger A, Morgans AK, Morris MJ, Mrabti H, Mukherji D, Murphy DG, Murthy V, Nguyen PL, Oh WK, Ost P, O'Sullivan JM, Padhani AR, Pezaro CJ, Poon DMC, Pritchard CC, Rabah DM, Rathkopf D, Reiter RE, Rubin MA, Ryan CJ, Saad F, Sade JP, Sartor O, Scher HI, Sharifi N, Skoneczna I, Soule H, Spratt DE, Srinivas S, Sternberg CN, Steuber T, Suzuki H, Sydes MR, Taplin ME, Tilki D, Türkeri L, Turco F, Uemura H, Uemura H, Ürün Y, Vale CL, van Oort I, Vapiwala N, Walz J, Yamoah K, Ye D, Yu EY, Zapatero A, Zilli T, Omlin A. PMID: 37003085.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    17. Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer. Cancer Res. 2023 01 18; 83(2):301-315. Chou J, Egusa EA, Wang S, Badura ML, Lee F, Bidkar AP, Zhu J, Shenoy T, Trepka K, Robinson TM, Steri V, Huang J, Wang Y, Small EJ, Chan E, Stohr BA, Ashworth A, Delafontaine B, Rottey S, Cooke KS, Hashemi Sadraei N, Yu B, Salvati M, Bailis JM, Feng FY, Flavell RR, Aggarwal R. PMID: 36351060; PMCID: PMC10263373.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansAnimals
    18. Implementation of a Telehealth Genetic Testing Station to Deliver Germline Testing for Men With Prostate Cancer. JCO Oncol Pract. 2023 05; 19(5):e773-e783. Kwon DH, Kwon DH, Gordon KM, Tong B, Borno HT, Beigh M, Fattah D, Schleicher A, Aggarwal RR, Blanco AM, Small EJ, Dhawan M. PMID: 36649492.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCellsPHPublic Health
    19. Intrinsic Molecular Subtypes of Metastatic Castration-Resistant Prostate Cancer. Clin Cancer Res. 2022 12 15; 28(24):5396-5404. Feng E, Rydzewski NR, Zhang M, Lundberg A, Bootsma M, Helzer KT, Lang JM, Aggarwal R, Small EJ, Quigley DA, Sjöström M, Zhao SG. PMID: 36260524; PMCID: PMC9890931.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    20. Quality of life for men with metastatic castrate-resistant prostate cancer participating in an aerobic and resistance exercise pilot intervention. Urol Oncol. 2023 03; 41(3):146.e1-146.e11. Langlais CS, Chen YH, Van Blarigan EL, Chan JM, Ryan CJ, Zhang L, Borno HT, Newton RU, Luke A, Bang AS, Panchal N, Tenggara I, Schultz B, Lavaki E, Pinto N, Aggarwal R, Friedlander T, Koshkin VS, Harzstark AL, Small EJ, Kenfield SA. PMID: 36528473.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    21. Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022. Eur Urol. 2023 03; 83(3):267-293. Gillessen S, Bossi A, Davis ID, de Bono J, Fizazi K, James ND, Mottet N, Shore N, Small E, Smith M, Sweeney C, Tombal B, Antonarakis ES, Aparicio AM, Armstrong AJ, Attard G, Beer TM, Beltran H, Bjartell A, Blanchard P, Briganti A, Bristow RG, Bulbul M, Caffo O, Castellano D, Castro E, Cheng HH, Chi KN, Chowdhury S, Clarke CS, Clarke N, Daugaard G, De Santis M, Duran I, Eeles R, Efstathiou E, Efstathiou J, Ngozi Ekeke O, Evans CP, Fanti S, Feng FY, Fonteyne V, Fossati N, Frydenberg M, George D, Gleave M, Gravis G, Halabi S, Heinrich D, Herrmann K, Higano C, Hofman MS, Horvath LG, Hussain M, Jereczek-Fossa BA, Jones R, Kanesvaran R, Kellokumpu-Lehtinen PL, Khauli RB, Klotz L, Kramer G, Leibowitz R, Logothetis CJ, Mahal BA, Maluf F, Mateo J, Matheson D, Mehra N, Merseburger A, Morgans AK, Morris MJ, Mrabti H, Mukherji D, Murphy DG, Murthy V, Nguyen PL, Oh WK, Ost P, O'Sullivan JM, Padhani AR, Pezaro C, Poon DMC, Pritchard CC, Rabah DM, Rathkopf D, Reiter RE, Rubin MA, Ryan CJ, Saad F, Pablo Sade J, Sartor OA, Scher HI, Sharifi N, Skoneczna I, Soule H, Spratt DE, Srinivas S, Sternberg CN, Steuber T, Suzuki H, Sydes MR, Taplin ME, Tilki D, Türkeri L, Turco F, Uemura H, Uemura H, Ürün Y, Vale CL, van Oort I, Vapiwala N, Walz J, Yamoah K, Ye D, Yu EY, Zapatero A, Zilli T, Omlin A. PMID: 36494221; PMCID: PMC7614721.
      View in: PubMed   Mentions: 20     Fields:    Translation:Humans
    22. Analysis of Serious Adverse Event Reporting for Patients Enrolled in Cancer Clinical Trials During the COVID-19 Pandemic. JAMA Oncol. 2022 12 01; 8(12):1849-1851. Ragavan MV, Legaspi N, LaLanne A, Hong JC, Small EJ, Borno HT. PMID: 36301577; PMCID: PMC9614670.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansPHPublic Health
    23. Serial stereotactic body radiation therapy for oligometastatic prostate cancer detected by novel PET-based radiotracers. Urol Oncol. 2023 03; 41(3):145.e7-145.e15. Kwon DH, Shakhnazaryan N, Shui D, Hong JC, Mohamad O, de Kouchkovsky I, Borno HT, Bose R, Chou J, Desai A, Fong L, Friedlander TW, Koshkin VS, Aggarwal RR, Feng FY, Hope TA, Small EJ. PMID: 36435709.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    24. Assessing Unique Risk Factors for COVID-19 Complications Among Cancer Patients: A Multi-ethnic Cohort Study. J Immigr Minor Health. 2023 Jun; 25(3):624-633. Borno HT, Kim MO, Tolstykh I, Lin A, Hong JC, Yousefi S, Zhang S, McKay RR, Harismendy O, Razavi P, Cinar P, Rugo H, Koshkin VS, Rabow M, Wang C, Bailey A, Small EJ. PMID: 36344859; PMCID: PMC9640901.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    25. The 5-Hydroxymethylcytosine Landscape of Prostate Cancer. Cancer Res. 2022 11 02; 82(21):3888-3902. Sjöström M, Zhao SG, Levy S, Zhang M, Ning Y, Shrestha R, Lundberg A, Herberts C, Foye A, Aggarwal R, Hua JT, Li H, Bergamaschi A, Maurice-Dror C, Maheshwari A, Chen S, Ng SWS, Ye W, Petricca J, Fraser M, Chesner L, Perry MD, Moreno-Rodriguez T, Chen WS, Alumkal JJ, Chou J, Morgans AK, Beer TM, Thomas GV, Gleave M, Lloyd P, Phillips T, McCarthy E, Haffner MC, Zoubeidi A, Annala M, Reiter RE, Rettig MB, Witte ON, Fong L, Bose R, Huang FW, Luo J, Bjartell A, Lang JM, Mahajan NP, Lara PN, Evans CP, Tran PT, Posadas EM, He C, Cui XL, Huang J, Zwart W, Gilbert LA, Maher CA, Boutros PC, Chi KN, Ashworth A, Small EJ, He HH, Wyatt AW, Quigley DA, Feng FY. PMID: 36251389; PMCID: PMC9627125.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    26. Clinical characteristics associated with falls in patients with non-metastatic castration-resistant prostate cancer treated with apalutamide. Prostate Cancer Prostatic Dis. 2023 03; 26(1):156-161. Pollock Y, Smith MR, Saad F, Chowdhury S, Oudard S, Hadaschik B, Olmos D, Lee JY, Uemura H, Bhaumik A, Londhe A, Rooney B, Brookman-May SD, De Porre P, Mundle SD, Small EJ. PMID: 36209239.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    27. Randomized, Open-Label Phase 2 Study of Apalutamide plus Androgen Deprivation Therapy versus Apalutamide Monotherapy versus Androgen Deprivation Monotherapy in Patients with Biochemically Recurrent Prostate Cancer. Prostate Cancer. 2022; 2022:5454727. Aggarwal R, Alumkal JJ, Szmulewitz RZ, Higano CS, Bryce AH, Lopez-Gitlitz A, McCarthy SA, Miladinovic B, McQuarrie K, Thomas S, Zhang K, Small EJ. PMID: 36212187; PMCID: PMC9534720.
      View in: PubMed   Mentions:
    28. Transcriptional profiling of matched patient biopsies clarifies molecular determinants of enzalutamide-induced lineage plasticity. Nat Commun. 2022 09 15; 13(1):5345. Westbrook TC, Guan X, Rodansky E, Flores D, Liu CJ, Udager AM, Patel RA, Haffner MC, Hu YM, Sun D, Beer TM, Foye A, Aggarwal R, Quigley DA, Youngren JF, Ryan CJ, Gleave M, Wang Y, Huang J, Coleman I, Morrissey C, Nelson PS, Evans CP, Lara P, Reiter RE, Witte O, Rettig M, Wong CK, Weinstein AS, Uzunangelov V, Stuart JM, Thomas GV, Feng FY, Small EJ, Yates JA, Xia Z, Alumkal JJ. PMID: 36109521; PMCID: PMC9477876.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    29. Hypoxia-inducible factor pathway genes predict survival in metastatic clear cell renal cell carcinoma. Urol Oncol. 2022 11; 40(11):495.e1-495.e10. Tamukong PK, Kuhlmann P, You S, Su S, Wang Y, Yoon S, Gong J, Figlin RA, Janes JL, Freedland SJ, Halabi S, Small EJ, Rini BI, Kim HL. PMID: 35973929.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    30. Deep whole-genome ctDNA chronology of treatment-resistant prostate cancer. Nature. 2022 08; 608(7921):199-208. Herberts C, Annala M, Sipola J, Ng SWS, Chen XE, Nurminen A, Korhonen OV, Munzur AD, Beja K, Schönlau E, Bernales CQ, Ritch E, Bacon JVW, Lack NA, Nykter M, Aggarwal R, Small EJ, Gleave ME, SU2C/PCF West Coast Prostate Cancer Dream Team, Quigley DA, Feng FY, Chi KN, Wyatt AW. PMID: 35859180.
      View in: PubMed   Mentions: 35     Fields:    Translation:HumansCells
    31. CUB Domain-Containing Protein 1 (CDCP1) Is a Target for Radioligand Therapy in Castration-Resistant Prostate Cancer, including PSMA Null Disease. Clin Cancer Res. 2022 07 15; 28(14):3066-3075. Zhao N, Chopra S, Trepka K, Wang YH, Sakhamuri S, Hooshdaran N, Kim H, Zhou J, Lim SA, Leung KK, Egusa EA, Zhu J, Zhang L, Foye A, Sriram R, Chan E, Seo Y, Feng FY, Small EJ, Chou J, Wells JA, Aggarwal R, Evans MJ. PMID: 35604681; PMCID: PMC9288514.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansAnimals
    32. Predictive Biomarkers of Overall Survival in Patients with Metastatic Renal Cell Carcinoma Treated with IFNα ± Bevacizumab: Results from CALGB 90206 (Alliance). Clin Cancer Res. 2022 07 01; 28(13):2771-2778. Nixon AB, Halabi S, Liu Y, Starr MD, Brady JC, Shterev I, Luo B, Hurwitz HI, Febbo PG, Rini BI, Beltran H, Small EJ, Morris MJ, George DJ. PMID: 34965953; PMCID: PMC9240110.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    33. Skeletal-related events after abiraterone or enzalutamide in patients with metastatic castration-resistant prostate cancer: A population-based study using the SEER-Medicare linked dataset. Urol Oncol. 2022 08; 40(8):379.e17-379.e24. Kwon DH, Kwon DH, Paciorek A, Zhang L, Borno HT, Bucknor M, Small EJ, Aggarwal RR. PMID: 35750560.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    34. COVID-19 Outcomes Among Patients With Cancer: Observations From the University of California Cancer Consortium COVID-19 Project Outcomes Registry. Oncologist. 2022 05 06; 27(5):398-406. Borno HT, Kim MO, Hong JC, Yousefi S, Lin A, Tolstykh I, Zhang S, McKay RR, Harismendy O, Cinar P, Rugo H, Koshkin VS, Rabow M, Wang C, Bailey A, Small EJ. PMID: 35348771; PMCID: PMC9074994.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    35. Mobile Clinical Trial Matching Technology in Medical Oncology Clinic: A Pilot Feasibility Study. JCO Clin Cancer Inform. 2022 05; 6:e2100182. Borno HT, Zhang L, Zhang S, Kaplan C, Palmer NR, Bell A, Bakke B, Lin A, Aggarwal R, Small EJ. PMID: 35584338; PMCID: PMC9173564.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    36. Diet and Health-related Quality of Life Among Men on Active Surveillance for Early-stage Prostate Cancer: The Men's Eating and Living Study (Cancer and Leukemia Group 70807 [Alliance]). Eur Urol Focus. 2022 11; 8(6):1607-1616. Kellogg Parsons J, Zahrieh D, Patel D, Mohler JL, Chen RC, Paskett ED, Liu H, Peil ES, Rock CL, Hahn O, Taylor J, Van Veldhuizen PJ, Small EJ, Morris MJ, Naughton MJ, Pierce JP, Marshall J. PMID: 35504836; PMCID: PMC10365132.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    37. Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021. Eur Urol. 2022 07; 82(1):115-141. Gillessen S, Armstrong A, Attard G, Beer TM, Beltran H, Bjartell A, Bossi A, Briganti A, Bristow RG, Bulbul M, Caffo O, Chi KN, Clarke CS, Clarke N, Davis ID, de Bono JS, Duran I, Eeles R, Efstathiou E, Efstathiou J, Ekeke ON, Evans CP, Fanti S, Feng FY, Fizazi K, Frydenberg M, George D, Gleave M, Halabi S, Heinrich D, Higano C, Hofman MS, Hussain M, James N, Jones R, Kanesvaran R, Khauli RB, Klotz L, Leibowitz R, Logothetis C, Maluf F, Millman R, Morgans AK, Morris MJ, Mottet N, Mrabti H, Murphy DG, Murthy V, Oh WK, Ost P, O'Sullivan JM, Padhani AR, Parker C, Poon DMC, Pritchard CC, Rabah DM, Rathkopf D, Reiter RE, Rubin M, Ryan CJ, Saad F, Sade JP, Sartor O, Scher HI, Shore N, Skoneczna I, Small E, Smith M, Soule H, Spratt DE, Sternberg CN, Suzuki H, Sweeney C, Sydes MR, Taplin ME, Tilki D, Tombal B, Türkeri L, Uemura H, Uemura H, van Oort I, Yamoah K, Ye D, Zapatero A, Omlin A. PMID: 35450732.
      View in: PubMed   Mentions: 24     Fields:    Translation:Humans
    38. Corrigendum to "What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021" [Eur Urol 82(1):6-11]. Eur Urol. 2022 Jul; 82(1):e18-e19. Turco F, Armstrong A, Attard G, Beer TM, Beltran H, Bjartell A, Bossi A, Briganti A, Bristow RG, Bulbul M, Caffo O, Chi KN, Clarke C, Clarke N, Davis ID, de Bono J, Duran I, Eeles R, Efstathiou E, Efstathiou J, Evans CP, Fanti S, Feng FY, Fizazi K, Frydenberg M, George D, Gleave M, Halabi S, Heinrich D, Higano C, Hofman MS, Hussain M, James N, Jones R, Kanesvaran R, Khauli RB, Klotz L, Leibowitz R, Logothetis C, Maluf F, Millman R, Morgans AK, Morris MJ, Mottet N, Mrabti H, Murphy DG, Murthy V, Oh WK, Ekeke ON, Ost P, O'Sullivan JM, Padhani AR, Parker C, Poon DMC, Pritchard CC, Rabah DM, Rathkopf D, Reiter RE, Rubin M, Ryan CJ, Saad F, Sade JP, Sartor O, Scher HI, Shore N, Skoneczna I, Small E, Smith M, Soule H, Spratt D, Sternberg CN, Suzuki H, Sweeney C, Sydes M, Taplin ME, Tilki D, Tombal B, Türkeri L, Uemura H, Uemura H, van Oort I, Yamoah K, Ye D, Zapatero A, Gillessen S, Omlin A. PMID: 35440417; PMCID: PMC9012951.
      View in: PubMed   Mentions:    Fields:    
    39. A Phase Ib/II Study of the CDK4/6 Inhibitor Ribociclib in Combination with Docetaxel plus Prednisone in Metastatic Castration-Resistant Prostate Cancer. Clin Cancer Res. 2022 04 14; 28(8):1531-1539. de Kouchkovsky I, Rao A, Carneiro BA, Zhang L, Lewis C, Phone A, Small EJ, Friedlander T, Fong L, Paris PL, Ryan CJ, Szmulewitz RZ, Aggarwal R. PMID: 35176163.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCTClinical Trials
    40. APOBEC Mutational Signature and Tumor Mutational Burden as Predictors of Clinical Outcomes and Treatment Response in Patients With Advanced Urothelial Cancer. Front Oncol. 2022; 12:816706. Natesan D, Zhang L, Martell HJ, Jindal T, Devine P, Stohr B, Espinosa-Mendez C, Grenert J, Van Ziffle J, Joseph N, Umetsu S, Onodera C, Turski M, Chan E, Desai A, Aggarwal R, Wong A, Porten S, Chou J, Friedlander T, Fong L, Small EJ, Sweet-Cordero A, Koshkin VS. PMID: 35321431; PMCID: PMC8935010.
      View in: PubMed   Mentions: 3  
    41. Implementation of a Multisite Financial Reimbursement Program in Cancer Clinical Trials Integrated With Patient Navigation: A Pilot Randomized Clinical Trial. JCO Oncol Pract. 2022 06; 18(6):e915-e924. Borno HT, Zhang L, Zhang S, Lin TK, Skafel A, Nieves E, Dornsife D, Johnson R, Rhoads K, Small E, Spicer D. PMID: 35196064; PMCID: PMC9191303.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    42. What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021. Eur Urol. 2022 07; 82(1):6-11. Turco F, Armstrong A, Attard G, Beer TM, Beltran H, Bjartell A, Bossi A, Briganti A, Bristow RG, Bulbul M, Caffo O, Chi KN, Clarke C, Clarke N, Davis ID, de Bono J, Duran I, Eeles R, Efstathiou E, Efstathiou J, Evans CP, Fanti S, Feng FY, Fizazi K, Frydenberg M, George D, Gleave M, Halabi S, Heinrich D, Higano C, Hofman MS, Hussain M, James N, Jones R, Kanesvaran R, Khauli RB, Klotz L, Leibowitz R, Logothetis C, Maluf F, Millman R, Morgans AK, Morris MJ, Mottet N, Mrabti H, Murphy DG, Murthy V, Oh WK, Ekeke Onyeanunam N, Ost P, O'Sullivan JM, Padhani AR, Parker C, Poon DMC, Pritchard CC, Rabah DM, Rathkopf D, Reiter RE, Rubin M, Ryan CJ, Saad F, Pablo Sade J, Sartor O, Scher HI, Shore N, Skoneczna I, Small E, Smith M, Soule H, Spratt D, Sternberg CN, Suzuki H, Sweeney C, Sydes M, Taplin ME, Tilki D, Tombal B, Türkeri L, Uemura H, Uemura H, van Oort I, Yamoah K, Ye D, Zapatero A, Gillessen S, Omlin A. PMID: 35393158; PMCID: PMC8849852.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansPHPublic Health
    43. Mobile Audio Recording Technology to Promote Informed Decision Making in Advanced Prostate Cancer. JCO Oncol Pract. 2022 05; 18(5):e648-e658. Kwon DH, Karthikeyan S, Chang A, Borno HT, Koshkin VS, Desai A, Bose R, Friedlander T, Rodvelt T, Li P, Small EJ, Aggarwal RR, Belkora J. PMID: 34932386.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    44. The long noncoding RNA H19 regulates tumor plasticity in neuroendocrine prostate cancer. Nat Commun. 2021 12 21; 12(1):7349. Singh N, Ramnarine VR, Song JH, Pandey R, Padi SKR, Nouri M, Olive V, Kobelev M, Okumura K, McCarthy D, Hanna MM, Mukherjee P, Sun B, Lee BR, Parker JB, Chakravarti D, Warfel NA, Zhou M, Bearss JJ, Gibb EA, Alshalalfa M, Karnes RJ, Small EJ, Aggarwal R, Feng F, Wang Y, Buttyan R, Zoubeidi A, Rubin M, Gleave M, Slack FJ, Davicioni E, Beltran H, Collins C, Kraft AS. PMID: 34934057; PMCID: PMC8692330.
      View in: PubMed   Mentions: 31     Fields:    Translation:HumansAnimalsCells
    45. Deep Prostate-specific Antigen Response following Addition of Apalutamide to Ongoing Androgen Deprivation Therapy and Long-term Clinical Benefit in SPARTAN. Eur Urol. 2022 Feb; 81(2):184-192. Saad F, Small EJ, Feng FY, Graff JN, Olmos D, Hadaschik BA, Oudard S, Londhe A, Bhaumik A, Lopez-Gitlitz A, Thomas S, Mundle SD, Chowdhury S, Smith MR. PMID: 34916086.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    46. Lack of consensus identifies important areas for future clinical research: Advanced Prostate Cancer Consensus Conference (APCCC) 2019 findings. Eur J Cancer. 2022 01; 160:24-60. Vogl UM, Beer TM, Davis ID, Shore ND, Sweeney CJ, Ost P, Attard G, Bossi A, de Bono J, Drake CG, Efstathiou E, Fanti S, Fizazi K, Halabi S, James N, Mottet N, Padhani AR, Roach M, Rubin M, Sartor O, Small E, Smith MR, Soule H, Sydes MR, Tombal B, Omlin A, Gillessen S, APCCC 2019 expert panel. PMID: 34844839.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    47. Prognosis Associated With Luminal and Basal Subtypes of Metastatic Prostate Cancer. JAMA Oncol. 2021 Nov 01; 7(11):1644-1652. Aggarwal R, Rydzewski NR, Zhang L, Foye A, Kim W, Helzer KT, Bakhtiar H, Chang SL, Perry MD, Gleave M, Reiter RE, Huang J, Evans CP, Alumkal JJ, Lang JM, Yu M, Quigley DA, Sjöström M, Small EJ, Feng FY, Zhao SG. PMID: 34554200; PMCID: PMC8461554.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    48. Feasibility, safety, and acceptability of a remotely monitored exercise pilot CHAMP: A Clinical trial of High-intensity Aerobic and resistance exercise for Metastatic castrate-resistant Prostate cancer. Cancer Med. 2021 11; 10(22):8058-8070. Kenfield SA, Van Blarigan EL, Panchal N, Bang A, Zhang L, Graff RE, Chen YH, Ryan CJ, Luke A, Newton RU, Tenggara I, Schultz B, Wang E, Lavaki E, Zuniga K, Pinto N, Borno H, Aggarwal R, Friedlander T, Koshkin VS, Harzstark A, Small E, Chan JM. PMID: 34636156; PMCID: PMC8607248.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    49. Predicting cancer drug TARGETS - TreAtment Response Generalized Elastic-neT Signatures. NPJ Genom Med. 2021 Sep 21; 6(1):76. Rydzewski NR, Peterson E, Lang JM, Yu M, Laura Chang S, Sjöström M, Bakhtiar H, Song G, Helzer KT, Bootsma ML, Chen WS, Shrestha RM, Zhang M, Quigley DA, Aggarwal R, Small EJ, Wahl DR, Feng FY, Zhao SG. PMID: 34548481; PMCID: PMC8455625.
      View in: PubMed   Mentions: 7  
    50. Accelerating cancer clinical trial recruitment through a financial reimbursement program integrated with patient navigation: an interrupted time series analysis. J Cancer Policy. 2021 12; 30:100305. Borno HT, Lin TK, Zhang S, Skafel A, Lalanne A, Dornsife D, Johnson R, Spicer D, Small EJ, Rhoads KF. PMID: 35559801.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    51. Health-related Quality of Life at the SPARTAN Final Analysis of Apalutamide for Nonmetastatic Castration-resistant Prostate Cancer Patients Receiving Androgen Deprivation Therapy. Eur Urol Focus. 2022 07; 8(4):958-967. Oudard S, Hadaschik B, Saad F, Cella D, Basch E, Graff JN, Uemura H, Dibaj S, Li S, Brookman-May SD, De Porre P, Bevans KB, Trudeau JJ, Small EJ, Smith MR. PMID: 34479838.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    52. An integrated functional and clinical genomics approach reveals genes driving aggressive metastatic prostate cancer. Nat Commun. 2021 07 29; 12(1):4601. Das R, Sjöström M, Shrestha R, Yogodzinski C, Egusa EA, Chesner LN, Chen WS, Chou J, Dang DK, Swinderman JT, Ge A, Hua JT, Kabir S, Quigley DA, Small EJ, Ashworth A, Feng FY, Gilbert LA. PMID: 34326322; PMCID: PMC8322386.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansAnimalsCells
    53. A multidisciplinary team-based approach with lifestyle modification and symptom management to address the impact of androgen deprivation therapy in prostate cancer: A randomized phase II study. Urol Oncol. 2021 10; 39(10):730.e9-730.e15. Pollock Y, Zhang L, Kenfield SA, Van Blarigan EL, Rodvelt T, Rabow M, Macaire G, Weinberg R, Topp K, Friedlander T, Lin A, Fong L, Kim W, Ma B, Hough J, Lee M, Paciorek A, Ryan CJ, Chan JM, Small E, Aggarwal R. PMID: 34304981.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    54. Association of Molecular Subtypes With Differential Outcome to Apalutamide Treatment in Nonmetastatic Castration-Resistant Prostate Cancer. JAMA Oncol. 2021 Jul 01; 7(7):1005-1014. Feng FY, Thomas S, Saad F, Gormley M, Yu MK, Ricci DS, Rooney B, Brookman-May S, McCarthy S, Olmos D, Chowdhury S, Hadaschik B, Liu Y, Davicioni E, Smith MR, Small EJ. PMID: 34081076; PMCID: PMC8176389.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    55. BET Bromodomain Inhibition Blocks an AR-Repressed, E2F1-Activated Treatment-Emergent Neuroendocrine Prostate Cancer Lineage Plasticity Program. Clin Cancer Res. 2021 09 01; 27(17):4923-4936. Kim DH, Sun D, Storck WK, Welker Leng K, Jenkins C, Coleman DJ, Sampson D, Guan X, Kumaraswamy A, Rodansky ES, Urrutia JA, Schwartzman JA, Zhang C, Beltran H, Labrecque MP, Morrissey C, Lucas JM, Coleman IM, Nelson PS, Corey E, Handelman SK, Sexton JZ, Aggarwal R, Abida W, Feng FY, Small EJ, Spratt DE, Bankhead A, Rao A, Gesner EM, Attwell S, Lakhotia S, Campeau E, Yates JA, Xia Z, Alumkal JJ. PMID: 34145028; PMCID: PMC8416959.
      View in: PubMed   Mentions: 25     Fields:    Translation:HumansCells
    56. Blood Biomarker Landscape in Patients with High-risk Nonmetastatic Castration-Resistant Prostate Cancer Treated with Apalutamide and Androgen-Deprivation Therapy as They Progress to Metastatic Disease. Clin Cancer Res. 2021 08 15; 27(16):4539-4548. Smith MR, Thomas S, Gormley M, Chowdhury S, Olmos D, Oudard S, Feng FY, Rajpurohit Y, Urtishak K, Ricci DS, Rooney B, Lopez-Gitlitz A, Yu M, Wyatt AW, Li M, Attard G, Small EJ. PMID: 34112710.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    57. Randomized Phase III Trial of Gemcitabine and Cisplatin With Bevacizumab or Placebo in Patients With Advanced Urothelial Carcinoma: Results of CALGB 90601 (Alliance). J Clin Oncol. 2021 08 01; 39(22):2486-2496. Rosenberg JE, Ballman KA, Halabi S, Atherton PJ, Mortazavi A, Sweeney C, Stadler WM, Teply BA, Picus J, Tagawa ST, Katragadda S, Vaena D, Misleh J, Hoimes C, Plimack ER, Flaig TW, Dreicer R, Bajorin D, Hahn O, Small EJ, Morris MJ. PMID: 33989025; PMCID: PMC8462587.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansCTClinical Trials
    58. TERT promoter mutations and other prognostic factors in patients with advanced urothelial carcinoma treated with an immune checkpoint inhibitor. J Immunother Cancer. 2021 05; 9(5). de Kouchkovsky I, Zhang L, Philip EJ, Wright F, Kim DM, Natesan D, Kwon D, Ho H, Ho S, Chan E, Porten SP, Wong AC, Desai A, Huang FW, Chou J, Oh DY, Pruthi RS, Fong L, Small EJ, Friedlander TW, Koshkin VS. PMID: 33980590; PMCID: PMC8118032.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCells
    59. Pre-existing immune status associated with response to combination of sipuleucel-T and ipilimumab in patients with metastatic castration-resistant prostate cancer. J Immunother Cancer. 2021 05; 9(5). Sinha M, Zhang L, Subudhi S, Chen B, Marquez J, Liu EV, Allaire K, Cheung A, Ng S, Nguyen C, Friedlander TW, Aggarwal R, Spitzer M, Allison JP, Small EJ, Sharma P, Fong L. PMID: 33986125; PMCID: PMC8126308.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCellsCTClinical Trials
    60. Prostate-specific Membrane Antigen and Fluciclovine Transporter Genes are Associated with Variable Clinical Features and Molecular Subtypes of Primary Prostate Cancer. Eur Urol. 2021 06; 79(6):717-721. Chu CE, Alshalalfa M, Sjöström M, Zhao SG, Liu Y, Chou J, Herlemann A, Mahal B, Kishan AU, Spratt DE, Cooperberg M, Small E, Wong A, Porten S, Hope TA, Ross AE, Davicioni E, Nguyen P, Karnes RJ, Carroll PR, Schaeffer E, Feng FY. PMID: 33840559.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    61. Prostate-specific antigen nadir and testosterone level at prostate-specific antigen failure following radiation and androgen suppression therapy for unfavorable-risk prostate cancer and the risk of all-cause and prostate cancer-specific mortality. Cancer. 2021 08 01; 127(15):2623-2630. Bitterman DS, Chen MH, Wu J, Renshaw AA, Loffredo M, Kantoff PW, Small EJ, D'Amico AV. PMID: 33823065; PMCID: PMC9436009.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    62. Baseline Testosterone Levels in Men with Clinically Localized High-Risk Prostate Cancer Treated with Radical Prostatectomy with or without Neoadjuvant Chemohormonal Therapy (Alliance). J Urol. 2021 Aug; 206(2):319-324. Eastham JA, Heller G, Hillman DW, Hahn OM, Parsons JK, Mohler JL, Small EJ, Morris M. PMID: 33780276; PMCID: PMC8273099.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    63. Differential treatment outcomes in BRCA1/2-, CDK12-, and ATM-mutated metastatic castration-resistant prostate cancer. Cancer. 2021 06 15; 127(12):1965-1973. Kwon DH, Chou J, Yip SM, Reimers MA, Zhang L, Wright F, Dhawan MS, Borno HT, Desai A, Aggarwal RR, Wyatt AW, Small EJ, Alva AS, Chi KN, Feng FY, Koshkin VS. PMID: 33690902.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    64. Examining reporting and representation of patients with cancer in COVID-19 clinical trials. Cancer Rep (Hoboken). 2021 08; 4(4):e1355. Rabow M, Wang C, Zhang S, Tahir PM, Small EJ, Borno HT. PMID: 33621447; PMCID: PMC7995191.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    65. Androgen-deprivation therapy and SARS-CoV-2 in men with prostate cancer: findings from the University of California Health System registry. Ann Oncol. 2021 05; 32(5):678-679. Kwon DH, Vashisht R, Borno HT, Aggarwal RR, Small EJ, Butte AJ, Huang FW. PMID: 33571636; PMCID: PMC7870099.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCells
    66. MicroRNA-574 regulates FAM210A expression and influences pathological cardiac remodeling. EMBO Mol Med. 2021 02 05; 13(2):e12710. Wu J, Venkata Subbaiah KC, Jiang F, Hedaya O, Mohan A, Yang T, Welle K, Ghaemmaghami S, Tang WHW, Small E, Yan C, Yao P. PMID: 33369227; PMCID: PMC7863409.
      View in: PubMed   Mentions: 17     Fields:    Translation:AnimalsCells
    67. Accelerating precision medicine in metastatic prostate cancer. Nat Cancer. 2020 11; 1(11):1041-1053. Mateo J, McKay R, Abida W, Aggarwal R, Alumkal J, Alva A, Feng F, Gao X, Graff J, Hussain M, Karzai F, Montgomery B, Oh W, Patel V, Rathkopf D, Rettig M, Schultz N, Smith M, Solit D, Sternberg C, Van Allen E, VanderWeele D, Vinson J, Soule HR, Chinnaiyan A, Small E, Simons JW, Dahut W, Miyahira AK, Beltran H. PMID: 34258585; PMCID: PMC8274325.
      View in: PubMed   Mentions: 33     Fields:    Translation:Humans
    68. Autoantibody Landscape in Patients with Advanced Prostate Cancer. Clin Cancer Res. 2020 12 01; 26(23):6204-6214. Chen WS, Haynes WA, Waitz R, Kamath K, Vega-Crespo A, Shrestha R, Zhang M, Foye A, Baselga Carretero I, Perez Garcilazo I, Zhang M, Zhao SG, Sjöström M, Quigley DA, Chou J, Beer TM, Rettig M, Gleave M, Evans CP, Lara P, Chi KN, Reiter RE, Alumkal JJ, Ashworth A, Aggarwal R, Small EJ, Daugherty PS, Ribas A, Oh DY, Shon JC, Feng FY. PMID: 32967941; PMCID: PMC7710628.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    69. Apalutamide and Overall Survival in Prostate Cancer. Eur Urol. 2021 01; 79(1):150-158. Smith MR, Saad F, Chowdhury S, Oudard S, Hadaschik BA, Graff JN, Olmos D, Mainwaring PN, Lee JY, Uemura H, De Porre P, Smith AA, Brookman-May SD, Li S, Zhang K, Rooney B, Lopez-Gitlitz A, Small EJ. PMID: 32907777.
      View in: PubMed   Mentions: 65     Fields:    Translation:Humans
    70. Copy Number Loss of 17q22 Is Associated with Enzalutamide Resistance and Poor Prognosis in Metastatic Castration-Resistant Prostate Cancer. Clin Cancer Res. 2020 09 01; 26(17):4616-4624. Guan X, Sun D, Lu E, Urrutia JA, Reiter RE, Rettig M, Evans CP, Lara P, Gleave M, Beer TM, Thomas GV, Huang J, Aggarwal RR, Quigley DA, Foye A, Chen WS, Youngren J, Weinstein AS, Stuart JM, Feng FY, Small EJ, Xia Z, Alumkal JJ. PMID: 32727885; PMCID: PMC7484240.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCells
    71. Cancer and Leukemia Group B 90203 (Alliance): Radical Prostatectomy With or Without Neoadjuvant Chemohormonal Therapy in Localized, High-Risk Prostate Cancer. J Clin Oncol. 2020 09 10; 38(26):3042-3050. Eastham JA, Heller G, Halabi S, Monk JP, Beltran H, Gleave M, Evans CP, Clinton SK, Szmulewitz RZ, Coleman J, Hillman DW, Watt CR, George S, Sanda MG, Hahn OM, Taplin ME, Parsons JK, Mohler JL, Small EJ, Morris MJ. PMID: 32706639; PMCID: PMC7479762.
      View in: PubMed   Mentions: 32     Fields:    Translation:Humans
    72. A Phase Ib/IIa Study of the Pan-BET Inhibitor ZEN-3694 in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer. Clin Cancer Res. 2020 10 15; 26(20):5338-5347. Aggarwal RR, Schweizer MT, Nanus DM, Pantuck AJ, Heath EI, Campeau E, Attwell S, Norek K, Snyder M, Bauman L, Lakhotia S, Feng FY, Small EJ, Abida W, Alumkal JJ. PMID: 32694156; PMCID: PMC7572827.
      View in: PubMed   Mentions: 48     Fields:    Translation:HumansCTClinical Trials
    73. The DNA methylation landscape of advanced prostate cancer. Nat Genet. 2020 08; 52(8):778-789. Zhao SG, Chen WS, Li H, Foye A, Zhang M, Sjöström M, Aggarwal R, Playdle D, Liao A, Alumkal JJ, Das R, Chou J, Hua JT, Barnard TJ, Bailey AM, Chow ED, Perry MD, Dang HX, Yang R, Moussavi-Baygi R, Zhang L, Alshalalfa M, Laura Chang S, Houlahan KE, Shiah YJ, Beer TM, Thomas G, Chi KN, Gleave M, Zoubeidi A, Reiter RE, Rettig MB, Witte O, Yvonne Kim M, Fong L, Spratt DE, Morgan TM, Bose R, Huang FW, Li H, Chesner L, Shenoy T, Goodarzi H, Asangani IA, Sandhu S, Lang JM, Mahajan NP, Lara PN, Evans CP, Febbo P, Batzoglou S, Knudsen KE, He HH, Huang J, Zwart W, Costello JF, Luo J, Tomlins SA, Wyatt AW, Dehm SM, Ashworth A, Gilbert LA, Boutros PC, Farh K, Chinnaiyan AM, Maher CA, Small EJ, Quigley DA, Feng FY. PMID: 32661416; PMCID: PMC7454228.
      View in: PubMed   Mentions: 122     Fields:    Translation:HumansCells
    74. Down-regulation of ADRB2 expression is associated with small cell neuroendocrine prostate cancer and adverse clinical outcomes in castration-resistant prostate cancer. Urol Oncol. 2020 12; 38(12):931.e9-931.e16. Kwon DH, Zhang L, Quigley DA, Foye A, Chen WS, Wong CK, Feng FY, Bailey A, Huang J, Stuart JM, Friedl V, Weinstein AS, Beer TM, Alumkal JJ, Rettig M, Gleave M, Lara PN, Thomas GV, Li P, Lui A, Small EJ, Aggarwal RR. PMID: 32624423.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    75. Efficacy and Safety Exposure-Response Relationships of Apalutamide in Patients with Nonmetastatic Castration-Resistant Prostate Cancer. Clin Cancer Res. 2020 09 01; 26(17):4460-4467. Perez-Ruixo C, Ackaert O, Ouellet D, Chien C, Uemura H, Olmos D, Mainwaring P, Lee JY, Yu MK, Perez-Ruixo JJ, Smith MR, Small EJ. PMID: 32561663.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCTClinical Trials
    76. Efficacy and safety of apalutamide in Japanese patients with nonmetastatic castration-resistant prostate cancer: a subgroup analysis of a randomized, double-blind, placebo-controlled, Phase-3 study. Prostate Int. 2020 Dec; 8(4):190-197. Uemura H, Satoh T, Tsumura H, Arai G, Imanaka K, Shibayama K, Fujii K, Rooney B, Lopez-Gitlitz A, Espina B, Perez-Ruixo C, Small EJ, Smith M. PMID: 33425798; PMCID: PMC7767934.
      View in: PubMed   Mentions: 8  
    77. Transcriptional profiling identifies an androgen receptor activity-low, stemness program associated with enzalutamide resistance. Proc Natl Acad Sci U S A. 2020 06 02; 117(22):12315-12323. Alumkal JJ, Sun D, Lu E, Beer TM, Thomas GV, Latour E, Aggarwal R, Cetnar J, Ryan CJ, Tabatabaei S, Bailey S, Turina CB, Quigley DA, Guan X, Foye A, Youngren JF, Urrutia J, Huang J, Weinstein AS, Friedl V, Rettig M, Reiter RE, Spratt DE, Gleave M, Evans CP, Stuart JM, Chen Y, Feng FY, Small EJ, Witte ON, Xia Z. PMID: 32424106; PMCID: PMC7275746.
      View in: PubMed   Mentions: 59     Fields:    Translation:HumansCTClinical Trials
    78. Clinical and genomic characterization of Low PSA Secretors: a unique subset of metastatic castration resistant prostate cancer. Prostate Cancer Prostatic Dis. 2021 03; 24(1):81-87. Aggarwal R, Romero GR, Friedl V, Weinstein A, Foye A, Huang J, Feng F, Stuart JM, Small EJ. PMID: 32286548.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    79. Does the COVID-19 outbreak identify a broader need for an urgent transformation of cancer clinical trials research? Contemp Clin Trials. 2020 05; 92:105997. Borno HT, Small EJ. PMID: 32272172; PMCID: PMC7194679.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCellsPHPublic Health
    80. Survival of African-American and Caucasian men after sipuleucel-T immunotherapy: outcomes from the PROCEED registry. Prostate Cancer Prostatic Dis. 2020 09; 23(3):517-526. Sartor O, Armstrong AJ, Ahaghotu C, McLeod DG, Cooperberg MR, Penson DF, Kantoff PW, Vogelzang NJ, Hussain A, Pieczonka CM, Shore ND, Quinn DI, Small EJ, Heath EI, Tutrone RF, Schellhammer PF, Harmon M, Chang NN, Sheikh NA, Brown B, Freedland SJ, Higano CS. PMID: 32111923; PMCID: PMC7423504.
      View in: PubMed   Mentions: 51     Fields:    Translation:Humans
    81. Comparative Survival of Asian and White Metastatic Castration-Resistant Prostate Cancer Men Treated With Docetaxel. JNCI Cancer Spectr. 2020 Apr; 4(2):pkaa003. Halabi S, Dutta S, Tangen CM, Rosenthal M, Petrylak DP, Thompson IM, Chi KN, De Bono JS, Araujo JC, Logothetis C, Eisenberger MA, Quinn DI, Fizazi K, Morris MJ, Higano CS, Tannock IF, Small EJ, Kelly WK. PMID: 32368717; PMCID: PMC7190204.
      View in: PubMed   Mentions:    Fields:    
    82. Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. Eur Urol. 2020 04; 77(4):508-547. Gillessen S, Attard G, Beer TM, Beltran H, Bjartell A, Bossi A, Briganti A, Bristow RG, Chi KN, Clarke N, Davis ID, de Bono J, Drake CG, Duran I, Eeles R, Efstathiou E, Evans CP, Fanti S, Feng FY, Fizazi K, Frydenberg M, Gleave M, Halabi S, Heidenreich A, Heinrich D, Higano CTS, Hofman MS, Hussain M, James N, Kanesvaran R, Kantoff P, Khauli RB, Leibowitz R, Logothetis C, Maluf F, Millman R, Morgans AK, Morris MJ, Mottet N, Mrabti H, Murphy DG, Murthy V, Oh WK, Ost P, O'Sullivan JM, Padhani AR, Parker C, Poon DMC, Pritchard CC, Reiter RE, Roach M, Rubin M, Ryan CJ, Saad F, Sade JP, Sartor O, Scher HI, Shore N, Small E, Smith M, Soule H, Sternberg CN, Steuber T, Suzuki H, Sweeney C, Sydes MR, Taplin ME, Tombal B, Türkeri L, van Oort I, Zapatero A, Omlin A. PMID: 32001144.
      View in: PubMed   Mentions: 139     Fields:    Translation:Humans
    83. Effect of a Behavioral Intervention to Increase Vegetable Consumption on Cancer Progression Among Men With Early-Stage Prostate Cancer: The MEAL Randomized Clinical Trial. JAMA. 2020 01 14; 323(2):140-148. Parsons JK, Zahrieh D, Mohler JL, Paskett E, Hansel DE, Kibel AS, Liu H, Seisler DK, Natarajan L, White M, Hahn O, Taylor J, Hartman SJ, Stroup SP, Van Veldhuizen P, Hall L, Small EJ, Morris MJ, Pierce JP, Marshall J. PMID: 31935026; PMCID: PMC6990696.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansAnimals
    84. Germline polymorphisms associated with impaired survival outcomes and somatic tumor alterations in advanced prostate cancer. Prostate Cancer Prostatic Dis. 2020 06; 23(2):316-323. Chen WS, Feng EL, Aggarwal R, Foye A, Beer TM, Alumkal JJ, Gleave M, Chi KN, Reiter RE, Rettig MB, Evans CP, Small EJ, Sharifi N, Zhao SG. PMID: 31745256; PMCID: PMC7529063.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    85. A step towards equitable clinical trial recruitment: a protocol for the development and preliminary testing of an online prostate cancer health information and clinical trial matching tool. Pilot Feasibility Stud. 2019; 5:123. Borno HT, Bakke BM, Kaplan C, Hebig-Prophet A, Chao J, Kim YJ, Yeager J, Cinar P, Small E, Boscardin C, Gonzales R. PMID: 31720002; PMCID: PMC6839161.
      View in: PubMed   Mentions: 3  
    86. Relationship Between Metastasis-free Survival and Overall Survival in Patients With Nonmetastatic Castration-resistant Prostate Cancer. Clin Genitourin Cancer. 2020 04; 18(2):e180-e189. Smith MR, Mehra M, Nair S, Lawson J, Small EJ. PMID: 31980408.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    87. Hyperpolarized 13C-pyruvate MRI detects real-time metabolic flux in prostate cancer metastases to bone and liver: a clinical feasibility study. Prostate Cancer Prostatic Dis. 2020 06; 23(2):269-276. Chen HY, Aggarwal R, Bok RA, Ohliger MA, Zhu Z, Lee P, Gordon JW, van Criekinge M, Carvajal L, Slater JB, Larson PEZ, Small EJ, Kurhanewicz J, Vigneron DB. PMID: 31685983; PMCID: PMC7196510.
      View in: PubMed   Mentions: 38     Fields:    Translation:Humans
    88. Apalutamide and overall survival in non-metastatic castration-resistant prostate cancer. Ann Oncol. 2019 11 01; 30(11):1813-1820. Small EJ, Saad F, Chowdhury S, Oudard S, Hadaschik BA, Graff JN, Olmos D, Mainwaring PN, Lee JY, Uemura H, De Porre P, Smith AA, Zhang K, Lopez-Gitlitz A, Smith MR. PMID: 31560066; PMCID: PMC6927320.
      View in: PubMed   Mentions: 33     Fields:    Translation:HumansCTClinical Trials
    89. How current reporting practices may mask differences: A call for examining cancer-specific demographic enrollment patterns in cancer treatment clinical trials. Contemp Clin Trials Commun. 2019 Dec; 16:100476. Borno HT, Small EJ, Zhang L, DeRouen MC, Griffin A, McGuire J, Ryan CJ, Hiatt RA, Kaplan CP. PMID: 31872154; PMCID: PMC6915794.
      View in: PubMed   Mentions: 5  
    90. Clinical Outcomes in Cyclin-dependent Kinase 12 Mutant Advanced Prostate Cancer. Eur Urol. 2020 03; 77(3):333-341. Reimers MA, Yip SM, Zhang L, Cieslik M, Dhawan M, Montgomery B, Wyatt AW, Chi KN, Small EJ, Chinnaiyan AM, Alva AS, Feng FY, Chou J. PMID: 31640893; PMCID: PMC7365609.
      View in: PubMed   Mentions: 30     Fields:    Translation:Humans
    91. Ethnic disparities among men with prostate cancer undergoing germline testing. Urol Oncol. 2020 03; 38(3):80.e1-80.e7. Kwon DH, Kwon DH, Borno HT, Cheng HH, Zhou AY, Small EJ. PMID: 31630993.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCells
    92. Prostate-Specific Membrane Antigen Ligand Positron Emission Tomography in Men with Nonmetastatic Castration-Resistant Prostate Cancer. Clin Cancer Res. 2019 12 15; 25(24):7448-7454. Fendler WP, Weber M, Iravani A, Hofman MS, Calais J, Czernin J, Ilhan H, Saad F, Small EJ, Smith MR, Perez PM, Hope TA, Rauscher I, Londhe A, Lopez-Gitlitz A, Cheng S, Maurer T, Herrmann K, Eiber M, Hadaschik B. PMID: 31511295.
      View in: PubMed   Mentions: 76     Fields:    Translation:Humans
    93. Cabozantinib Versus Sunitinib for Untreated Patients with Advanced Renal Cell Carcinoma of Intermediate or Poor Risk: Subgroup Analysis of the Alliance A031203 CABOSUN trial. Oncologist. 2019 11; 24(11):1497-1501. George DJ, Hessel C, Halabi S, Michaelson MD, Hahn O, Walsh M, Picus J, Small EJ, Dakhil S, Feldman DR, Mangeshkar M, Scheffold C, Morris MJ, Choueiri TK. PMID: 31399500; PMCID: PMC6853096.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCTClinical Trials
    94. The Role of Lineage Plasticity in Prostate Cancer Therapy Resistance. Clin Cancer Res. 2019 12 01; 25(23):6916-6924. Beltran H, Hruszkewycz A, Scher HI, Hildesheim J, Isaacs J, Yu EY, Kelly K, Lin D, Dicker A, Arnold J, Hecht T, Wicha M, Sears R, Rowley D, White R, Gulley JL, Lee J, Diaz Meco M, Small EJ, Shen M, Knudsen K, Goodrich DW, Lotan T, Zoubeidi A, Sawyers CL, Rudin CM, Loda M, Thompson T, Rubin MA, Tawab-Amiri A, Dahut W, Nelson PS. PMID: 31363002; PMCID: PMC6891154.
      View in: PubMed   Mentions: 145     Fields:    Translation:Humans
    95. Treatment of advanced renal cell carcinoma patients with cabozantinib, an oral multityrosine kinase inhibitor of MET, AXL and VEGF receptors. Future Oncol. 2019 Jul; 15(20):2337-2348. Desai A, Small EJ. PMID: 31184937.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCells
    96. Assessment of 68Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer: A Prospective Single-Arm Clinical Trial. JAMA Oncol. 2019 Jun 01; 5(6):856-863. Fendler WP, Calais J, Eiber M, Flavell RR, Mishoe A, Feng FY, Nguyen HG, Reiter RE, Rettig MB, Okamoto S, Emmett L, Zacho HD, Ilhan H, Wetter A, Rischpler C, Schoder H, Burger IA, Gartmann J, Smith R, Small EJ, Slavik R, Carroll PR, Herrmann K, Czernin J, Hope TA. PMID: 30920593; PMCID: PMC6567829.
      View in: PubMed   Mentions: 231     Fields:    Translation:HumansCTClinical Trials
    97. Androgen decline and survival during docetaxel therapy in metastatic castration resistant prostate cancer (mCRPC). Prostate Cancer Prostatic Dis. 2020 03; 23(1):66-73. Ryan CJ, Dutta S, Kelly WK, Russell C, Small EJ, Morris MJ, Taplin ME, Halabi S, From The Alliance for Clinical Trials in Oncology Genitourinary Committee. PMID: 31053766; PMCID: PMC6825875.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    98. Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2019 05 01; 17(5):479-505. Mohler JL, Antonarakis ES, Armstrong AJ, D'Amico AV, Davis BJ, Dorff T, Eastham JA, Enke CA, Farrington TA, Higano CS, Horwitz EM, Hurwitz M, Ippolito JE, Kane CJ, Kuettel MR, Lang JM, McKenney J, Netto G, Penson DF, Plimack ER, Pow-Sang JM, Pugh TJ, Richey S, Roach M, Rosenfeld S, Schaeffer E, Shabsigh A, Small EJ, Spratt DE, Srinivas S, Tward J, Shead DA, Freedman-Cass DA. PMID: 31085757.
      View in: PubMed   Mentions: 471     Fields:    Translation:Humans
    99. Germline and Somatic Mutations in Prostate Cancer for the Clinician. J Natl Compr Canc Netw. 2019 05 01; 17(5):515-521. Cheng HH, Sokolova AO, Schaeffer EM, Small EJ, Higano CS. PMID: 31085765.
      View in: PubMed   Mentions: 48     Fields:    Translation:Humans
    100. Incidentally Detected Oropharyngeal Squamous Cell Carcinoma on 18F-Fluciclovine PET/CT. Clin Nucl Med. 2019 May; 44(5):e367-e369. Raghavan K, Wen KW, Small EJ, Ha P, Flavell RR. PMID: 30829856.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    101. Novel RB1-Loss Transcriptomic Signature Is Associated with Poor Clinical Outcomes across Cancer Types. Clin Cancer Res. 2019 Jul 15; 25(14):4290-4299. Chen WS, Alshalalfa M, Zhao SG, Liu Y, Mahal BA, Quigley DA, Wei T, Davicioni E, Rebbeck TR, Kantoff PW, Maher CA, Knudsen KE, Small EJ, Nguyen PL, Feng FY. PMID: 31010837; PMCID: PMC7883384.
      View in: PubMed   Mentions: 26     Fields:    Translation:HumansCells
    102. Genomic Drivers of Poor Prognosis and Enzalutamide Resistance in Metastatic Castration-resistant Prostate Cancer. Eur Urol. 2019 11; 76(5):562-571. Chen WS, Aggarwal R, Zhang L, Zhao SG, Thomas GV, Beer TM, Quigley DA, Foye A, Playdle D, Huang J, Lloyd P, Lu E, Sun D, Guan X, Rettig M, Gleave M, Evans CP, Youngren J, True L, Lara P, Kothari V, Xia Z, Chi KN, Reiter RE, Maher CA, Feng FY, Small EJ, Alumkal JJ, West Coast Prostate Cancer Dream Team. PMID: 30928160; PMCID: PMC6764911.
      View in: PubMed   Mentions: 61     Fields:    Translation:Humans
    103. Whole-Genome and Transcriptional Analysis of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer Demonstrates Intraclass Heterogeneity. Mol Cancer Res. 2019 06; 17(6):1235-1240. Aggarwal RR, Quigley DA, Huang J, Zhang L, Beer TM, Rettig MB, Reiter RE, Gleave ME, Thomas GV, Foye A, Playdle D, Lloyd P, Chi KN, Evans CP, Lara PN, Feng FY, Alumkal JJ, Small EJ. PMID: 30918106; PMCID: PMC6548614.
      View in: PubMed   Mentions: 34     Fields:    Translation:HumansCells
    104. MEK-ERK signaling is a therapeutic target in metastatic castration resistant prostate cancer. Prostate Cancer Prostatic Dis. 2019 12; 22(4):531-538. Nickols NG, Nazarian R, Zhao SG, Tan V, Uzunangelov V, Xia Z, Baertsch R, Neeman E, Gao AC, Thomas GV, Howard L, De Hoedt AM, Stuart J, Goldstein T, Chi K, Gleave ME, Graff JN, Beer TM, Drake JM, Evans CP, Aggarwal R, Foye A, Feng FY, Small EJ, Aronson WJ, Freedland SJ, Witte ON, Huang J, Alumkal JJ, Reiter RE, Rettig MB. PMID: 30804427; PMCID: PMC6853839.
      View in: PubMed   Mentions: 43     Fields:    Translation:HumansCells
    105. Intertumoral Heterogeneity of 18F-FDG and 68Ga-PSMA Uptake in Prostate Cancer Pulmonary Metastases. Clin Nucl Med. 2019 Jan; 44(1):e28-e32. Perez PM, Hope TA, Behr SC, van Zante A, Small EJ, Flavell RR. PMID: 30394930.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    106. Overall Survival of Black and White Men With Metastatic Castration-Resistant Prostate Cancer Treated With Docetaxel. J Clin Oncol. 2019 02 10; 37(5):403-410. Halabi S, Dutta S, Tangen CM, Rosenthal M, Petrylak DP, Thompson IM, Chi KN, Araujo JC, Logothetis C, Quinn DI, Fizazi K, Morris MJ, Eisenberger MA, George DJ, De Bono JS, Higano CS, Tannock IF, Small EJ, Kelly WK. PMID: 30576268; PMCID: PMC6804881.
      View in: PubMed   Mentions: 53     Fields:    Translation:Humans
    107. Clinical and Genomic Implications of Luminal and Basal Subtypes Across Carcinomas. Clin Cancer Res. 2019 04 15; 25(8):2450-2457. Zhao SG, Chen WS, Das R, Chang SL, Tomlins SA, Chou J, Quigley DA, Dang HX, Barnard TJ, Mahal BA, Gibb EA, Liu Y, Davicioni E, Duska LR, Posadas EM, Jolly S, Spratt DE, Nguyen PL, Maher CA, Small EJ, Feng FY. PMID: 30573691.
      View in: PubMed   Mentions: 34     Fields:    Translation:HumansCells
    108. Reply to A. Dalla Volta et al. J Clin Oncol. 2019 02 01; 37(4):351-352. Aggarwal R, Huang J, Alumkal J, Feng FY, Zhang L, Stuart JM, Small EJ. PMID: 30557523.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    109. Phase I Study of CTT1057, an 18F-Labeled Imaging Agent with Phosphoramidate Core Targeting Prostate-Specific Membrane Antigen in Prostate Cancer. J Nucl Med. 2019 07; 60(7):910-916. Behr SC, Aggarwal R, VanBrocklin HF, Flavell RR, Gao K, Small EJ, Blecha J, Jivan S, Hope TA, Simko JP, Kurhanewicz J, Noworolski SM, Korn NJ, De Los Santos R, Cooperberg MR, Carroll PR, Nguyen HG, Greene KL, Langton-Webster B, Berkman CE, Seo Y. PMID: 30464040; PMCID: PMC6604687.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCTClinical Trials
    110. Apalutamide and its use in the treatment of prostate cancer. Future Oncol. 2019 Feb; 15(6):591-599. Borno HT, Small EJ. PMID: 30426794; PMCID: PMC6391625.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    111. Apalutamide in the treatment of castrate-resistant prostate cancer: evidence from clinical trials. Ther Adv Urol. 2018 Dec; 10(12):445-454. Koshkin VS, Small EJ. PMID: 30574205; PMCID: PMC6295778.
      View in: PubMed   Mentions: 1  
    112. Management of recurrent prostate cancer after radiotherapy: long-term results from CALGB 9687 (Alliance), a prospective multi-institutional salvage prostatectomy series. Prostate Cancer Prostatic Dis. 2019 05; 22(2):309-316. Mohler JL, Halabi S, Ryan ST, Al-Daghmin A, Sokoloff MH, Steinberg GD, Sanford BL, Eastham JA, Walther PJ, Morris MJ, Small EJ. PMID: 30385835; PMCID: PMC6494708.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    113. Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer. Cell. 2018 10 18; 175(3):889. Quigley DA, Dang HX, Zhao SG, Lloyd P, Aggarwal R, Alumkal JJ, Foye A, Kothari V, Perry MD, Bailey AM, Playdle D, Barnard TJ, Zhang L, Zhang J, Youngren JF, Cieslik MP, Parolia A, Beer TM, Thomas G, Chi KN, Gleave M, Lack NA, Zoubeidi A, Reiter RE, Rettig MB, Witte O, Ryan CJ, Fong L, Kim W, Friedlander T, Chou J, Li H, Das R, Li H, Moussavi-Baygi R, Goodarzi H, Gilbert LA, Lara PN, Evans CP, Goldstein TC, Stuart JM, Tomlins SA, Spratt DE, Cheetham RK, Cheng DT, Farh K, Gehring JS, Hakenberg J, Liao A, Febbo PG, Shon J, Sickler B, Batzoglou S, Knudsen KE, He HH, Huang J, Wyatt AW, Dehm SM, Ashworth A, Chinnaiyan AM, Maher CA, Small EJ, Feng FY. PMID: 30340047.
      View in: PubMed   Mentions: 64     Fields:    
    114. Corrigendum to 'Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update' [Eur J Cancer 94 (May 2018) 115-125]. Eur J Cancer. 2018 11; 103:287. Choueiri TK, Hessel C, Halabi S, Sanford B, Michaelson MD, Hahn O, Walsh M, Olencki T, Picus J, Small EJ, Dakhil S, Feldman DR, Mangeshkar M, Scheffold C, George D, Morris MJ. PMID: 30270112; PMCID: PMC6299293.
      View in: PubMed   Mentions: 4     Fields:    
    115. Itraconazole as a Noncastrating Treatment for Biochemically Recurrent Prostate Cancer: A Phase 2 Study. Clin Genitourin Cancer. 2019 Feb; 17(1):e92-e96. Lee M, Hong H, Kim W, Zhang L, Friedlander TW, Fong L, Lin AM, Small EJ, Wei XX, Rodvelt TJ, Miralda B, Stocksdale B, Ryan CJ, Aggarwal R. PMID: 30327180.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCTClinical Trials
    116. Effect of apalutamide on health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the SPARTAN randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2018 10; 19(10):1404-1416. Saad F, Cella D, Basch E, Hadaschik BA, Mainwaring PN, Oudard S, Graff JN, McQuarrie K, Li S, Hudgens S, Lawson J, Lopez-Gitlitz A, Yu MK, Smith MR, Small EJ. PMID: 30213449.
      View in: PubMed   Mentions: 44     Fields:    Translation:HumansCTClinical Trials
    117. Targeting CD46 for both adenocarcinoma and neuroendocrine prostate cancer. JCI Insight. 2018 09 06; 3(17). Su Y, Liu Y, Behrens CR, Bidlingmaier S, Lee NK, Aggarwal R, Sherbenou DW, Burlingame AL, Hann BC, Simko JP, Premasekharan G, Paris PL, Shuman MA, Seo Y, Small EJ, Liu B. PMID: 30185663; PMCID: PMC6171802.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansAnimalsCells
    118. A bilingual, Internet-based, targeted advertising campaign for prostate cancer clinical trials: Assessing the feasibility, acceptability, and efficacy of a novel recruitment strategy. Contemp Clin Trials Commun. 2018 Dec; 12:60-67. Kaplan CP, Siegel A, Leykin Y, Palmer NR, Borno H, Bielenberg J, Livaudais-Toman J, Ryan C, Small EJ. PMID: 30272035; PMCID: PMC6158958.
      View in: PubMed   Mentions: 5  
    119. DNA Repair Gene Alterations and PARP Inhibitor Response in Patients With Metastatic Castration-Resistant Prostate Cancer. J Natl Compr Canc Netw. 2018 08; 16(8):933-937. Lu E, Thomas GV, Chen Y, Wyatt AW, Lloyd P, Youngren J, Quigley D, Bergan R, Bailey S, Beer TM, Feng FY, Small EJ, Alumkal JJ. PMID: 30099369.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    120. Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer. Cell. 2018 07 26; 174(3):758-769.e9. Quigley DA, Dang HX, Zhao SG, Lloyd P, Aggarwal R, Alumkal JJ, Foye A, Kothari V, Perry MD, Bailey AM, Playdle D, Barnard TJ, Zhang L, Zhang J, Youngren JF, Cieslik MP, Parolia A, Beer TM, Thomas G, Chi KN, Gleave M, Lack NA, Zoubeidi A, Reiter RE, Rettig MB, Witte O, Ryan CJ, Fong L, Kim W, Friedlander T, Chou J, Li H, Das R, Li H, Moussavi-Baygi R, Goodarzi H, Gilbert LA, Lara PN, Evans CP, Goldstein TC, Stuart JM, Tomlins SA, Spratt DE, Cheetham RK, Cheng DT, Farh K, Gehring JS, Hakenberg J, Liao A, Febbo PG, Shon J, Sickler B, Batzoglou S, Knudsen KE, He HH, Huang J, Wyatt AW, Dehm SM, Ashworth A, Chinnaiyan AM, Maher CA, Small EJ, Feng FY. PMID: 30033370; PMCID: PMC6425931.
      View in: PubMed   Mentions: 263     Fields:    Translation:HumansCells
    121. Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study. J Clin Oncol. 2018 08 20; 36(24):2492-2503. Aggarwal R, Huang J, Alumkal JJ, Zhang L, Feng FY, Thomas GV, Weinstein AS, Friedl V, Zhang C, Witte ON, Lloyd P, Gleave M, Evans CP, Youngren J, Beer TM, Rettig M, Wong CK, True L, Foye A, Playdle D, Ryan CJ, Lara P, Chi KN, Uzunangelov V, Sokolov A, Newton Y, Beltran H, Demichelis F, Rubin MA, Stuart JM, Small EJ. PMID: 29985747; PMCID: PMC6366813.
      View in: PubMed   Mentions: 303     Fields:    Translation:HumansCellsCTClinical Trials
    122. Apalutamide and Metastasis-free Survival in Prostate Cancer. N Engl J Med. 2018 06 28; 378(26):2542. Smith MR, Yu MK, Small EJ. PMID: 29949495.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    123. Antigen-Specific CD8 Lytic Phenotype Induced by Sipuleucel-T in Hormone-Sensitive or Castration-Resistant Prostate Cancer and Association with Overall Survival. Clin Cancer Res. 2018 10 01; 24(19):4662-4671. Antonarakis ES, Small EJ, Petrylak DP, Quinn DI, Kibel AS, Chang NN, Dearstyne E, Harmon M, Campogan D, Haynes H, Vu T, Sheikh NA, Drake CG. PMID: 29858218; PMCID: PMC6481607.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCells
    124. Heterogeneous Flare in Prostate-specific Membrane Antigen Positron Emission Tomography Tracer Uptake with Initiation of Androgen Pathway Blockade in Metastatic Prostate Cancer. Eur Urol Oncol. 2018 05; 1(1):78-82. Aggarwal R, Wei X, Kim W, Small EJ, Ryan CJ, Carroll P, Cooperberg M, Evans MJ, Hope T. PMID: 31100231.
      View in: PubMed   Mentions: 42     Fields:    Translation:Humans
    125. Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update. Eur J Cancer. 2018 05; 94:115-125. Choueiri TK, Hessel C, Halabi S, Sanford B, Michaelson MD, Hahn O, Walsh M, Olencki T, Picus J, Small EJ, Dakhil S, Feldman DR, Mangeshkar M, Scheffold C, George D, Morris MJ. PMID: 29550566; PMCID: PMC6057479.
      View in: PubMed   Mentions: 113     Fields:    Translation:HumansCTClinical Trials
    126. Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer. N Engl J Med. 2018 Apr 12; 378(15):1408-1418. Smith MR, Saad F, Chowdhury S, Oudard S, Hadaschik BA, Graff JN, Olmos D, Mainwaring PN, Lee JY, Uemura H, Lopez-Gitlitz A, Trudel GC, Espina BM, Shu Y, Park YC, Rackoff WR, Yu MK, Small EJ, SPARTAN Investigators. PMID: 29420164.
      View in: PubMed   Mentions: 420     Fields:    Translation:HumansCTClinical Trials
    127. Clinical Variables Associated With Overall Survival in Metastatic Castration-Resistant Prostate Cancer Patients Treated With Sipuleucel-T Immunotherapy. Clin Genitourin Cancer. 2018 06; 16(3):184-190.e2. Wei XX, Perry J, Chang E, Zhang L, Hiatt RA, Ryan CJ, Small EJ, Fong L. PMID: 29352713.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCTClinical Trials
    128. Low testosterone at first prostate-specific antigen failure and assessment of risk of death in men with unfavorable-risk prostate cancer treated on prospective clinical trials. Cancer. 2018 04 01; 124(7):1383-1390. Atkins KM, Chen MH, Wu J, Renshaw AA, Loffredo M, Kantoff PW, Small EJ, D'Amico AV. PMID: 29266181; PMCID: PMC6034656.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    129. Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer. J Natl Cancer Inst. 2017 Dec 01; 109(12). Wyatt AW, Annala M, Aggarwal R, Beja K, Feng F, Youngren J, Foye A, Lloyd P, Nykter M, Beer TM, Alumkal JJ, Thomas GV, Reiter RE, Rettig MB, Evans CP, Gao AC, Chi KN, Small EJ, Gleave ME. PMID: 29206995; PMCID: PMC6440274.
      View in: PubMed   Mentions: 163     Fields:    Translation:HumansCells
    130. Optimal MRI sequences for 68Ga-PSMA-11 PET/MRI in evaluation of biochemically recurrent prostate cancer. EJNMMI Res. 2017 Sep 19; 7(1):77. Lake ST, Greene KL, Westphalen AC, Behr SC, Zagoria R, Small EJ, Carroll PR, Hope TA. PMID: 28929350; PMCID: PMC5605480.
      View in: PubMed   Mentions: 16  
    131. Redefining Hormonal Therapy for Advanced Prostate Cancer: Results from the LATITUDE and STAMPEDE Studies. Cancer Cell. 2017 09 11; 32(3):392. Small EJ. PMID: 28898699.
      View in: PubMed   Mentions: 3     Fields:    
    132. Redefining Hormonal Therapy for Advanced Prostate Cancer: Results from the LATITUDE and STAMPEDE Studies. Cancer Cell. 2017 07 10; 32(1):6-8. Small EJ. PMID: 28697343.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    133. Molecular Testing in Patients With Castration-Resistant Prostate Cancer and Its Impact on Clinical Decision Making. JCO Precis Oncol. 2017; 1. Tao DL, Bailey S, Beer TM, Foss E, Beckett B, Fung A, Foster BR, Guimaraes A, Cetnar JP, Graff JN, Eilers KM, Small EJ, Corless CL, Thomas GV, Alumkal JJ. PMID: 31650098; PMCID: PMC6812573.
      View in: PubMed   Mentions: 3     Fields:    
    134. Emerging Categories of Disease in Advanced Prostate Cancer and Their Therapeutic Implications. Oncology (Williston Park). 2017 06 15; 31(6):467-74. Aggarwal RR, Feng FY, Small EJ. PMID: 28620903.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    135. Real-Time Transferrin-Based PET Detects MYC-Positive Prostate Cancer. Mol Cancer Res. 2017 09; 15(9):1221-1229. Aggarwal R, Behr SC, Paris PL, Truillet C, Parker MFL, Huynh LT, Wei J, Hann B, Youngren J, Huang J, Premasekharan G, Ranatunga N, Chang E, Gao KT, Ryan CJ, Small EJ, Evans MJ. PMID: 28592703; PMCID: PMC5581675.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    136. High-Dose Abiraterone Acetate in Men With Castration Resistant Prostate Cancer. Clin Genitourin Cancer. 2017 12; 15(6):733-741.e1. Friedlander TW, Graff JN, Zejnullahu K, Anantharaman A, Zhang L, Paz R, Premasekharan G, Russell C, Huang Y, Kim W, Aggarwal RR, Lin AM, Fong L, Alumkal JJ, Beer TM, Sharifi N, Alyamani M, Dittamore R, Small EJ, Paris PL, Ryan CJ. PMID: 28655452.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCTClinical Trials
    137. Tackling non-metastatic castration-resistant prostate cancer: special considerations in treatment. Expert Rev Anticancer Ther. 2017 07; 17(7):625-633. Anantharaman A, Small EJ. PMID: 28532278.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    138. CT-Guided Bone Biopsies in Metastatic Castration-Resistant Prostate Cancer: Factors Predictive of Maximum Tumor Yield. J Vasc Interv Radiol. 2017 Aug; 28(8):1073-1081.e1. Holmes MG, Foss E, Joseph G, Foye A, Beckett B, Motamedi D, Youngren J, Thomas GV, Huang J, Aggarwal R, Alumkal JJ, Beer TM, Small EJ, Link TM. PMID: 28549709.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    139. Men's Eating and Living (MEAL) study (CALGB 70807 [Alliance]): recruitment feasibility and baseline demographics of a randomized trial of diet in men on active surveillance for prostate cancer. BJU Int. 2018 04; 121(4):534-539. Parsons JK, Pierce JP, Mohler J, Paskett E, Jung SH, Morris MJ, Small E, Hahn O, Humphrey P, Taylor J, Marshall J. PMID: 28437029; PMCID: PMC5654696.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansAnimalsCTClinical Trials
    140. Impact of 68Ga-PSMA-11 PET on Management in Patients with Biochemically Recurrent Prostate Cancer. J Nucl Med. 2017 12; 58(12):1956-1961. Hope TA, Aggarwal R, Chee B, Tao D, Greene KL, Cooperberg MR, Feng F, Chang A, Ryan CJ, Small EJ, Carroll PR. PMID: 28522741.
      View in: PubMed   Mentions: 55     Fields:    Translation:Humans
    141. Analysis of Circulating Cell-Free DNA Identifies Multiclonal Heterogeneity of BRCA2 Reversion Mutations Associated with Resistance to PARP Inhibitors. Cancer Discov. 2017 09; 7(9):999-1005. Quigley D, Alumkal JJ, Wyatt AW, Kothari V, Foye A, Lloyd P, Aggarwal R, Kim W, Lu E, Schwartzman J, Beja K, Annala M, Das R, Diolaiti M, Pritchard C, Thomas G, Tomlins S, Knudsen K, Lord CJ, Ryan C, Youngren J, Beer TM, Ashworth A, Small EJ, Feng FY. PMID: 28450426; PMCID: PMC5581695.
      View in: PubMed   Mentions: 126     Fields:    Translation:Humans
    142. Clinical Outcomes from Androgen Signaling-directed Therapy after Treatment with Abiraterone Acetate and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302. Eur Urol. 2017 07; 72(1):10-13. Smith MR, Saad F, Rathkopf DE, Mulders PFA, de Bono JS, Small EJ, Shore ND, Fizazi K, Kheoh T, Li J, De Porre P, Todd MB, Yu MK, Ryan CJ. PMID: 28314611.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCells
    143. Androgen receptor amplification is concordant between circulating tumor cells and biopsies from men undergoing treatment for metastatic castration resistant prostate cancer. Oncotarget. 2017 Sep 22; 8(42):71447-71455. Podolak J, Eilers K, Newby T, Slottke R, Tucker E, Olson SB, Lue HW, Youngren J, Aggarwal R, Small EJ, Graff JN, Alumkal JJ, Beer TM, Thomas GV. PMID: 29069718; PMCID: PMC5641061.
      View in: PubMed   Mentions: 14     Fields:    
    144. Treatment Outcomes and Tumor Loss of Heterozygosity in Germline DNA Repair-deficient Prostate Cancer. Eur Urol. 2017 07; 72(1):34-42. Annala M, Struss WJ, Warner EW, Beja K, Vandekerkhove G, Wong A, Khalaf D, Seppälä IL, So A, Lo G, Aggarwal R, Small EJ, Nykter M, Gleave ME, Chi KN, Wyatt AW. PMID: 28259476.
      View in: PubMed   Mentions: 92     Fields:    Translation:HumansCells
    145. A multicenter phase I study of cabazitaxel, mitoxantrone, and prednisone for chemotherapy-naïve patients with metastatic castration-resistant prostate cancer: A department of defense prostate cancer clinical trials consortium study. Urol Oncol. 2017 04; 35(4):149.e7-149.e13. Aggarwal R, Bryce A, Ryan CJ, Harzstark A, Derleth C, Kim W, Friedlander T, Lin AM, Rodvelt-Bagchi T, Dhawan M, Zhang L, Lee M, Siebeneck E, Hough J, Small EJ. PMID: 28161323.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    146. A Feasibility Study Showing [68Ga]Citrate PET Detects Prostate Cancer. Mol Imaging Biol. 2016 12; 18(6):946-951. Behr SC, Aggarwal R, Seo Y, Aparici CM, Chang E, Gao KT, Tao DH, Small EJ, Evans MJ. PMID: 27184068; PMCID: PMC6430569.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCTClinical Trials
    147. Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial. J Clin Oncol. 2017 02 20; 35(6):591-597. Choueiri TK, Halabi S, Sanford BL, Hahn O, Michaelson MD, Walsh MK, Feldman DR, Olencki T, Picus J, Small EJ, Dakhil S, George DJ, Morris MJ. PMID: 28199818; PMCID: PMC5455807.
      View in: PubMed   Mentions: 273     Fields:    Translation:HumansCTClinical Trials
    148. Targeting Adaptive Pathways in Metastatic Treatment-Resistant Prostate Cancer: Update on the Stand Up 2 Cancer/Prostate Cancer Foundation-Supported West Coast Prostate Cancer Dream Team. Eur Urol Focus. 2016 Dec; 2(5):469-471. Aggarwal R, Beer TM, Gleave M, Stuart JM, Rettig M, Evans CP, Youngren J, Alumkal JJ, Huang J, Thomas G, Witte O, Small EJ. PMID: 28723508.
      View in: PubMed   Mentions: 9     Fields:    
    149. Systemic GM-CSF Recruits Effector T Cells into the Tumor Microenvironment in Localized Prostate Cancer. Cancer Immunol Res. 2016 11; 4(11):948-958. Wei XX, Chan S, Kwek S, Lewis J, Dao V, Zhang L, Cooperberg MR, Ryan CJ, Lin AM, Friedlander TW, Rini B, Kane C, Simko JP, Carroll PR, Small EJ, Fong L. PMID: 27688020; PMCID: PMC5115633.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCells
    150. 68Ga-PSMA-11 PET Imaging of Response to Androgen Receptor Inhibition: First Human Experience. J Nucl Med. 2017 Jan; 58(1):81-84. Hope TA, Truillet C, Ehman EC, Afshar-Oromieh A, Aggarwal R, Ryan CJ, Carroll PR, Small EJ, Evans MJ. PMID: 27660139; PMCID: PMC5209643.
      View in: PubMed   Mentions: 87     Fields:    Translation:HumansAnimalsCells
    151. Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302. Eur Urol. 2017 04; 71(4):656-664. de Bono JS, Smith MR, Saad F, Rathkopf DE, Mulders PFA, Small EJ, Shore ND, Fizazi K, De Porre P, Kheoh T, Li J, Todd MB, Ryan CJ, Flaig TW. PMID: 27402060; PMCID: PMC5609503.
      View in: PubMed   Mentions: 27     Fields:    Translation:Humans
    152. An improved CTC isolation scheme for pairing with downstream genomics: Demonstrating clinical utility in metastatic prostate, lung and pancreatic cancer. Cancer Lett. 2016 09 28; 380(1):144-52. Premasekharan G, Gilbert E, Okimoto RA, Hamirani A, Lindquist KJ, Ngo VT, Roy R, Hough J, Edwards M, Paz R, Foye A, Sood R, Copren KA, Gubens M, Small EJ, Bivona TG, Collisson EA, Friedlander TW, Paris PL. PMID: 27343980.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCells
    153. Pharmacogenetic Discovery in CALGB (Alliance) 90401 and Mechanistic Validation of a VAC14 Polymorphism that Increases Risk of Docetaxel-Induced Neuropathy. Clin Cancer Res. 2016 Oct 01; 22(19):4890-4900. Hertz DL, Owzar K, Lessans S, Wing C, Jiang C, Kelly WK, Patel J, Halabi S, Furukawa Y, Wheeler HE, Sibley AB, Lassiter C, Weisman L, Watson D, Krens SD, Mulkey F, Renn CL, Small EJ, Febbo PG, Shterev I, Kroetz DL, Friedman PN, Mahoney JF, Carducci MA, Kelley MJ, Nakamura Y, Kubo M, Dorsey SG, Dolan ME, Morris MJ, Ratain MJ, McLeod HL. PMID: 27143689; PMCID: PMC5050068.
      View in: PubMed   Mentions: 31     Fields:    Translation:HumansAnimalsCTClinical Trials
    154. Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer. J Clin Oncol. 2016 05 10; 34(14):1652-9. Halabi S, Kelly WK, Ma H, Zhou H, Solomon NC, Fizazi K, Tangen CM, Rosenthal M, Petrylak DP, Hussain M, Vogelzang NJ, Thompson IM, Chi KN, de Bono J, Armstrong AJ, Eisenberger MA, Fandi A, Li S, Araujo JC, Logothetis CJ, Quinn DI, Morris MJ, Higano CS, Tannock IF, Small EJ. PMID: 26951312; PMCID: PMC4872320.
      View in: PubMed   Mentions: 174     Fields:    Translation:Humans
    155. Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. J Clin Oncol. 2016 Apr 20; 34(12):1402-18. Scher HI, Morris MJ, Stadler WM, Higano C, Basch E, Fizazi K, Antonarakis ES, Beer TM, Carducci MA, Chi KN, Corn PG, de Bono JS, Dreicer R, George DJ, Heath EI, Hussain M, Kelly WK, Liu G, Logothetis C, Nanus D, Stein MN, Rathkopf DE, Slovin SF, Ryan CJ, Sartor O, Small EJ, Smith MR, Sternberg CN, Taplin ME, Wilding G, Nelson PS, Schwartz LH, Halabi S, Kantoff PW, Armstrong AJ, Prostate Cancer Clinical Trials Working Group 3. PMID: 26903579; PMCID: PMC4872347.
      View in: PubMed   Mentions: 524     Fields:    Translation:Humans
    156. Prospects for the use of ipilimumab in treating advanced prostate cancer. Expert Opin Biol Ther. 2016; 16(3):421-32. Wei XX, Fong L, Small EJ. PMID: 26698365.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    157. Prostate Cancer, Version 1.2016. J Natl Compr Canc Netw. 2016 01; 14(1):19-30. Mohler JL, Armstrong AJ, Bahnson RR, D'Amico AV, Davis BJ, Eastham JA, Enke CA, Farrington TA, Higano CS, Horwitz EM, Hurwitz M, Kane CJ, Kawachi MH, Kuettel M, Lee RJ, Meeks JJ, Penson DF, Plimack ER, Pow-Sang JM, Raben D, Richey S, Roach M, Rosenfeld S, Schaeffer E, Skolarus TA, Small EJ, Sonpavde G, Srinivas S, Strope SA, Tward J, Shead DA, Freedman-Cass DA. PMID: 26733552.
      View in: PubMed   Mentions: 249     Fields:    Translation:Humans
    158. Optimal timing of sipuleucel-T treatment in metastatic castration-resistant prostate cancer. Can J Urol. 2015 Dec; 22(6):8048-55. Crawford ED, Petrylak DP, Higano CS, Kibel AS, Kantoff PW, Small EJ, Shore ND, Ferrari A. PMID: 26688132.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    159. Prior Endocrine Therapy Impact on Abiraterone Acetate Clinical Efficacy in Metastatic Castration-resistant Prostate Cancer: Post-hoc Analysis of Randomised Phase 3 Studies. Eur Urol. 2016 05; 69(5):924-32. Bellmunt J, Kheoh T, Yu MK, Smith MR, Small EJ, Mulders PF, Fizazi K, Rathkopf DE, Saad F, Scher HI, Taplin ME, Davis ID, Schrijvers D, Protheroe A, Molina A, De Porre P, Griffin TW, de Bono JS, Ryan CJ, Oudard S. PMID: 26508309; PMCID: PMC5465643.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCTClinical Trials
    160. Prostate Cancer Immunotherapy with Sipuleucel-T: Current Standards and Future Directions. Expert Rev Vaccines. 2015; 14(12):1529-41. Wei XX, Fong L, Small EJ. PMID: 26488270.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCells
    161. Knowledge and attitudes regarding clinical trials and willingness to participate among prostate cancer patients. Contemp Clin Trials. 2015 Nov; 45(Pt B):443-448. Kaplan CP, Nápoles AM, Narine S, Gregorich S, Livaudais-Toman J, Nguyen T, Leykin Y, Roach M, Small EJ. PMID: 26435199.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    162. A Molecular Model for Predicting Overall Survival in Patients with Metastatic Clear Cell Renal Carcinoma: Results from CALGB 90206 (Alliance). EBioMedicine. 2015 Nov; 2(11):1814-20. Kim HL, Halabi S, Li P, Mayhew G, Simko J, Nixon AB, Small EJ, Rini B, Morris MJ, Taplin ME, George D, Alliance for Clinical Trials in Oncology. PMID: 26870806; PMCID: PMC4740313.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    163. Impact of bone-targeted therapies in chemotherapy-naïve metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: post hoc analysis of study COU-AA-302. Eur Urol. 2015 Oct; 68(4):570-7. Saad F, Shore N, Van Poppel H, Rathkopf DE, Smith MR, de Bono JS, Logothetis CJ, de Souza P, Fizazi K, Mulders PF, Mainwaring P, Hainsworth JD, Beer TM, North S, Fradet Y, Griffin TA, De Porre P, Londhe A, Kheoh T, Small EJ, Scher HI, Molina A, Ryan CJ. PMID: 25985882; PMCID: PMC5056561.
      View in: PubMed   Mentions: 22     Fields:    Translation:Humans
    164. Preexisting Levels of CD4 T Cells Expressing PD-1 Are Related to Overall Survival in Prostate Cancer Patients Treated with Ipilimumab. Cancer Immunol Res. 2015 Sep; 3(9):1008-16. Kwek SS, Lewis J, Zhang L, Weinberg V, Greaney SK, Harzstark AL, Lin AM, Ryan CJ, Small EJ, Fong L. PMID: 25968455; PMCID: PMC4561203.
      View in: PubMed   Mentions: 37     Fields:    Translation:HumansCellsCTClinical Trials
    165. A Randomized Phase II Trial of Sipuleucel-T with Concurrent versus Sequential Abiraterone Acetate plus Prednisone in Metastatic Castration-Resistant Prostate Cancer. Clin Cancer Res. 2015 Sep 01; 21(17):3862-9. Small EJ, Lance RS, Gardner TA, Karsh LI, Fong L, McCoy C, DeVries T, Sheikh NA, GuhaThakurta D, Chang N, Redfern CH, Shore ND. PMID: 25925891.
      View in: PubMed   Mentions: 48     Fields:    Translation:HumansCellsCTClinical Trials
    166. Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer. Clin Cancer Res. 2015 May 15; 21(10):2315-24. Azad AA, Volik SV, Wyatt AW, Haegert A, Le Bihan S, Bell RH, Anderson SA, McConeghy B, Shukin R, Bazov J, Youngren J, Paris P, Thomas G, Small EJ, Wang Y, Gleave ME, Collins CC, Chi KN. PMID: 25712683.
      View in: PubMed   Mentions: 209     Fields:    Translation:HumansCells
    167. Progression-free survival: does a correlation with survival justify its role as a surrogate clinical endpoint? Cancer. 2015 Jun 01; 121(11):1906. Halabi S, Rini BI, Escudier B, Stadler WM, Small EJ. PMID: 25677867.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    168. Humoral Immune Response against Nontargeted Tumor Antigens after Treatment with Sipuleucel-T and Its Association with Improved Clinical Outcome. Clin Cancer Res. 2015 Aug 15; 21(16):3619-30. GuhaThakurta D, Sheikh NA, Fan LQ, Kandadi H, Meagher TC, Hall SJ, Kantoff PW, Higano CS, Small EJ, Gardner TA, Bailey K, Vu T, DeVries T, Whitmore JB, Frohlich MW, Trager JB, Drake CG. PMID: 25649018; PMCID: PMC4868054.
      View in: PubMed   Mentions: 78     Fields:    Translation:HumansCTClinical Trials
    169. Radiographic progression-free survival as a response biomarker in metastatic castration-resistant prostate cancer: COU-AA-302 results. J Clin Oncol. 2015 Apr 20; 33(12):1356-63. Morris MJ, Molina A, Small EJ, de Bono JS, Logothetis CJ, Fizazi K, de Souza P, Kantoff PW, Higano CS, Li J, Kheoh T, Larson SM, Matheny SL, Naini V, Burzykowski T, Griffin TW, Scher HI, Ryan CJ. PMID: 25624432; PMCID: PMC4881370.
      View in: PubMed   Mentions: 53     Fields:    Translation:HumansCTClinical Trials
    170. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2015 Feb; 16(2):152-60. Ryan CJ, Smith MR, Fizazi K, Saad F, Mulders PF, Sternberg CN, Miller K, Logothetis CJ, Shore ND, Small EJ, Carles J, Flaig TW, Taplin ME, Higano CS, de Souza P, de Bono JS, Griffin TW, De Porre P, Yu MK, Park YC, Li J, Kheoh T, Naini V, Molina A, Rathkopf DE, COU-AA-302 Investigators. PMID: 25601341.
      View in: PubMed   Mentions: 496     Fields:    Translation:HumansCTClinical Trials
    171. Intermittent Chemotherapy as a Platform for Testing Novel Agents in Patients With Metastatic Castration-Resistant Prostate Cancer: A Department of Defense Prostate Cancer Clinical Trials Consortium Randomized Phase II Trial of Intermittent Docetaxel With Prednisone With or Without Maintenance GM-CSF. Clin Genitourin Cancer. 2015 Jun; 13(3):e191-8. Aggarwal RR, Beer TM, Weinberg VK, Higano C, Taplin ME, Ryan CJ, Lin AM, Alumkal J, Graff JN, Nordquist LT, Herrera I, Small EJ. PMID: 25557266.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    172. Bevacizumab and the risk of arterial and venous thromboembolism in patients with metastatic, castration-resistant prostate cancer treated on Cancer and Leukemia Group B (CALGB) 90401 (Alliance). Cancer. 2015 Apr 01; 121(7):1025-31. Patel JN, Jiang C, Hertz DL, Mulkey FA, Owzar K, Halabi S, Ratain MJ, Friedman PN, Small EJ, Carducci MA, Mahoney JF, Kelley MJ, Morris MJ, Kelly WK, McLeod HL. PMID: 25417775; PMCID: PMC4368497.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    173. Sequential use of the androgen synthesis inhibitors ketoconazole and abiraterone acetate in castration-resistant prostate cancer and the predictive value of circulating androgens. Clin Cancer Res. 2014 Dec 15; 20(24):6269-76. Kim W, Zhang L, Wilton JH, Fetterly G, Mohler JL, Weinberg V, Morse A, Szmulewitz RZ, Friedlander TW, Fong L, Lin AM, Harzstark AL, Molina A, Small EJ, Ryan CJ. PMID: 25336698; PMCID: PMC4277885.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansCTClinical Trials
    174. Can targeting the androgen receptor in localized prostate cancer provide insights into why men with metastatic castration-resistant prostate cancer die? J Clin Oncol. 2014 Nov 20; 32(33):3689-91. Small EJ. PMID: 25311216.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    175. Small-cell/neuroendocrine prostate cancer: a growing threat? Oncology (Williston Park). 2014 Oct; 28(10):838-40. Aggarwal RR, Small EJ. PMID: 25323608.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    176. Activated lymphocyte recruitment into the tumor microenvironment following preoperative sipuleucel-T for localized prostate cancer. J Natl Cancer Inst. 2014 Nov; 106(11). Fong L, Carroll P, Weinberg V, Chan S, Lewis J, Corman J, Amling CL, Stephenson RA, Simko J, Sheikh NA, Sims RB, Frohlich MW, Small EJ. PMID: 25255802; PMCID: PMC4241888.
      View in: PubMed   Mentions: 106     Fields:    Translation:HumansCellsCTClinical Trials
    177. Reply to F. Valcamonico et al. J Clin Oncol. 2014 Nov 10; 32(32):3685. Smith MR, Halabi S, Small EJ. PMID: 25225438.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    178. A transient increase in eosinophils is associated with prolonged survival in men with metastatic castration-resistant prostate cancer who receive sipuleucel-T. Cancer Immunol Res. 2014 Oct; 2(10):988-99. McNeel DG, Gardner TA, Higano CS, Kantoff PW, Small EJ, Wener MH, Sims RB, DeVries T, Sheikh NA, Dreicer R. PMID: 25189164; PMCID: PMC4185225.
      View in: PubMed   Mentions: 32     Fields:    Translation:HumansCellsCTClinical Trials
    179. Inhibition of the androgen receptor by mineralocorticoids at levels physiologically achieved in serum in patients treated with abiraterone acetate. Prostate Cancer Prostatic Dis. 2014 Sep; 17(3):292-9. Kim W, Jones JO, Diamond M, Haqq C, Molina A, Small EJ, Ryan CJ. PMID: 25047002.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    180. Time to disease-related pain and first opioid use in patients with metastatic castration-resistant prostate cancer treated with sipuleucel-T. Prostate Cancer Prostatic Dis. 2014 Sep; 17(3):259-64. Small EJ, Higano CS, Kantoff PW, Whitmore JB, Frohlich MW, Petrylak DP. PMID: 24957547; PMCID: PMC4160816.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    181. Prostate cancer, version 2.2014. J Natl Compr Canc Netw. 2014 May; 12(5):686-718. Mohler JL, Kantoff PW, Armstrong AJ, Bahnson RR, Cohen M, D'Amico AV, Eastham JA, Enke CA, Farrington TA, Higano CS, Horwitz EM, Kane CJ, Kawachi MH, Kuettel M, Kuzel TM, Lee RJ, Malcolm AW, Miller D, Plimack ER, Pow-Sang JM, Raben D, Richey S, Roach M, Rohren E, Rosenfeld S, Schaeffer E, Small EJ, Sonpavde G, Srinivas S, Stein C, Strope SA, Tward J, Shead DA, Ho M, National Comprehensive Cancer Network. PMID: 24812137.
      View in: PubMed   Mentions: 129     Fields:    Translation:Humans
    182. Neuroendocrine prostate cancer: subtypes, biology, and clinical outcomes. J Natl Compr Canc Netw. 2014 May; 12(5):719-26. Aggarwal R, Zhang T, Small EJ, Armstrong AJ. PMID: 24812138.
      View in: PubMed   Mentions: 83     Fields:    Translation:Humans
    183. Response to subsequent docetaxel in a patient cohort with metastatic castration-resistant prostate cancer after abiraterone acetate treatment. Clin Genitourin Cancer. 2014 Oct; 12(5):e167-72. Aggarwal R, Harris A, Formaker C, Small EJ, Molina A, Griffin TW, Ryan CJ. PMID: 24787968.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCTClinical Trials
    184. Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302). Eur Urol. 2014 Nov; 66(5):815-25. Rathkopf DE, Smith MR, de Bono JS, Logothetis CJ, Shore ND, de Souza P, Fizazi K, Mulders PF, Mainwaring P, Hainsworth JD, Beer TM, North S, Fradet Y, Van Poppel H, Carles J, Flaig TW, Efstathiou E, Yu EY, Higano CS, Taplin ME, Griffin TW, Todd MB, Yu MK, Park YC, Kheoh T, Small EJ, Scher HI, Molina A, Ryan CJ, Saad F. PMID: 24647231; PMCID: PMC4418928.
      View in: PubMed   Mentions: 96     Fields:    Translation:HumansCTClinical Trials
    185. Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance). J Clin Oncol. 2014 Apr 10; 32(11):1143-50. Smith MR, Halabi S, Ryan CJ, Hussain A, Vogelzang N, Stadler W, Hauke RJ, Monk JP, Saylor P, Bhoopalam N, Saad F, Sanford B, Kelly WK, Morris M, Small EJ. PMID: 24590644; PMCID: PMC3970172.
      View in: PubMed   Mentions: 94     Fields:    Translation:HumansCTClinical Trials
    186. Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancer. J Clin Oncol. 2014 Mar 01; 32(7):671-7. Halabi S, Lin CY, Kelly WK, Fizazi KS, Moul JW, Kaplan EB, Morris MJ, Small EJ. PMID: 24449231; PMCID: PMC3927736.
      View in: PubMed   Mentions: 206     Fields:    Translation:Humans
    187. Prostate cancer, version 1.2014. J Natl Compr Canc Netw. 2013 Dec 01; 11(12):1471-9. Mohler JL, Kantoff PW, Armstrong AJ, Bahnson RR, Cohen M, D'Amico AV, Eastham JA, Enke CA, Farrington TA, Higano CS, Horwitz EM, Kawachi MH, Kuettel M, Lee RJ, Macvicar GR, Malcolm AW, Miller D, Plimack ER, Pow-Sang JM, Richey S, Roach M, Rohren E, Rosenfeld S, Small EJ, Srinivas S, Stein C, Strope SA, Tward J, Walsh PC, Shead DA, Ho M, National comprehensive cancer network. PMID: 24335682.
      View in: PubMed   Mentions: 41     Fields:    Translation:Humans
    188. Prognostic model predicting metastatic castration-resistant prostate cancer survival in men treated with second-line chemotherapy. J Natl Cancer Inst. 2013 Nov 20; 105(22):1729-37. Halabi S, Lin CY, Small EJ, Armstrong AJ, Kaplan EB, Petrylak D, Sternberg CN, Shen L, Oudard S, de Bono J, Sartor O. PMID: 24136890; PMCID: PMC3833929.
      View in: PubMed   Mentions: 63     Fields:    Translation:HumansCTClinical Trials
    189. Progression-free survival as a surrogate endpoint of overall survival in patients with metastatic renal cell carcinoma. Cancer. 2014 Jan 01; 120(1):52-60. Halabi S, Rini B, Escudier B, Stadler WM, Small EJ. PMID: 24347384; PMCID: PMC3869105.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCTClinical Trials
    190. Prostate-specific antigen changes as surrogate for overall survival in men with metastatic castration-resistant prostate cancer treated with second-line chemotherapy. J Clin Oncol. 2013 Nov 01; 31(31):3944-50. Halabi S, Armstrong AJ, Sartor O, de Bono J, Kaplan E, Lin CY, Solomon NC, Small EJ. PMID: 24101043; PMCID: PMC3805930.
      View in: PubMed   Mentions: 34     Fields:    Translation:HumansCTClinical Trials
    191. Metabolic imaging of patients with prostate cancer using hyperpolarized [1-¹³C]pyruvate. Sci Transl Med. 2013 Aug 14; 5(198):198ra108. Nelson SJ, Kurhanewicz J, Vigneron DB, Larson PE, Harzstark AL, Ferrone M, van Criekinge M, Chang JW, Bok R, Park I, Reed G, Carvajal L, Small EJ, Munster P, Weinberg VK, Ardenkjaer-Larsen JH, Chen AP, Hurd RE, Odegardstuen LI, Robb FJ, Tropp J, Murray JA. PMID: 23946197; PMCID: PMC4201045.
      View in: PubMed   Mentions: 599     Fields:    Translation:Humans
    192. Reply to C.M. Booth et al. J Clin Oncol. 2013 Sep 10; 31(26):3300. Goodwin PJ, Ballman KV, Small EJ, Levine M, Cannistra SA. PMID: 23943837.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    193. The effect of prior androgen synthesis inhibition on outcomes of subsequent therapy with docetaxel in patients with metastatic castrate-resistant prostate cancer: results from a retrospective analysis of a randomized phase 3 clinical trial (CALGB 90401) (Alliance). Cancer. 2013 Oct 15; 119(20):3636-43. Aggarwal R, Halabi S, Kelly WK, George D, Mahoney JF, Millard F, Stadler WM, Morris MJ, Kantoff P, Monk JP, Carducci M, Small EJ, Alliance for Clinical Trials in Oncology. PMID: 23913744; PMCID: PMC3795898.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCTClinical Trials
    194. Serum androgens as prognostic biomarkers in castration-resistant prostate cancer: results from an analysis of a randomized phase III trial. J Clin Oncol. 2013 Aug 01; 31(22):2791-8. Ryan CJ, Molina A, Li J, Kheoh T, Small EJ, Haqq CM, Grant RP, de Bono JS, Scher HI. PMID: 23816964; PMCID: PMC5569674.
      View in: PubMed   Mentions: 47     Fields:    Translation:HumansCTClinical Trials
    195. Penile cancer: Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2013 May 01; 11(5):594-615. Clark PE, Spiess PE, Agarwal N, Biagioli MC, Eisenberger MA, Greenberg RE, Herr HW, Inman BA, Kuban DA, Kuzel TM, Lele SM, Michalski J, Pagliaro L, Pal SK, Patterson A, Plimack ER, Pohar KS, Porter MP, Richie JP, Sexton WJ, Shipley WU, Small EJ, Trump DL, Wile G, Wilson TG, Dwyer M, Ho M, National Comprehensive Cancer Network. PMID: 23667209; PMCID: PMC4042432.
      View in: PubMed   Mentions: 61     Fields:    Translation:Humans
    196. Intermittent versus continuous androgen deprivation in prostate cancer. N Engl J Med. 2013 Apr 04; 368(14):1314-25. Hussain M, Tangen CM, Berry DL, Higano CS, Crawford ED, Liu G, Wilding G, Prescott S, Kanaga Sundaram S, Small EJ, Dawson NA, Donnelly BJ, Venner PM, Vaishampayan UN, Schellhammer PF, Quinn DI, Raghavan D, Ely B, Moinpour CM, Vogelzang NJ, Thompson IM. PMID: 23550669; PMCID: PMC3682658.
      View in: PubMed   Mentions: 180     Fields:    Translation:Humans
    197. Bladder cancer. J Natl Compr Canc Netw. 2013 Apr 01; 11(4):446-75. Clark PE, Agarwal N, Biagioli MC, Eisenberger MA, Greenberg RE, Herr HW, Inman BA, Kuban DA, Kuzel TM, Lele SM, Michalski J, Pagliaro LC, Pal SK, Patterson A, Plimack ER, Pohar KS, Porter MP, Richie JP, Sexton WJ, Shipley WU, Small EJ, Spiess PE, Trump DL, Wile G, Wilson TG, Dwyer M, Ho M, National Comprehensive Cancer Network (NCCN). PMID: 23584347.
      View in: PubMed   Mentions: 148     Fields:    Translation:Humans
    198. Is there a role for immune checkpoint blockade with ipilimumab in prostate cancer? Cancer Med. 2013 Apr; 2(2):243-52. Cha E, Small EJ. PMID: 23634292; PMCID: PMC3639663.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    199. Prognostic model for predicting survival of patients with metastatic urothelial cancer treated with cisplatin-based chemotherapy. J Natl Cancer Inst. 2013 Apr 03; 105(7):499-503. Apolo AB, Ostrovnaya I, Halabi S, Iasonos A, Philips GK, Rosenberg JE, Riches J, Small EJ, Milowsky MI, Bajorin DF. PMID: 23411591; PMCID: PMC3691944.
      View in: PubMed   Mentions: 40     Fields:    Translation:Humans
    200. Evaluation of treatment benefit in Journal of Clinical Oncology. J Clin Oncol. 2013 Mar 20; 31(9):1123-4. Goodwin PJ, Ballman KV, Small EJ, Cannistra SA. PMID: 23358984.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    201. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2013 Jan 10; 368(2):138-48. Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, Fizazi K, Mainwaring P, Piulats JM, Ng S, Carles J, Mulders PF, Basch E, Small EJ, Saad F, Schrijvers D, Van Poppel H, Mukherjee SD, Suttmann H, Gerritsen WR, Flaig TW, George DJ, Yu EY, Efstathiou E, Pantuck A, Winquist E, Higano CS, Taplin ME, Park Y, Kheoh T, Griffin T, Scher HI, Rathkopf DE, COU-AA-302 Investigators. PMID: 23228172; PMCID: PMC3683570.
      View in: PubMed   Mentions: 1006     Fields:    Translation:Humans
    202. Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial. J Clin Oncol. 2013 Feb 01; 31(4):412-9. Smith DC, Smith MR, Sweeney C, Elfiky AA, Logothetis C, Corn PG, Vogelzang NJ, Small EJ, Harzstark AL, Gordon MS, Vaishampayan UN, Haas NB, Spira AI, Lara PN, Lin CC, Srinivas S, Sella A, Schöffski P, Scheffold C, Weitzman AL, Hussain M. PMID: 23169517; PMCID: PMC4110249.
      View in: PubMed   Mentions: 192     Fields:    Translation:HumansCTClinical Trials
    203. Diversity of antigen-specific responses induced in vivo with CTLA-4 blockade in prostate cancer patients. J Immunol. 2012 Oct 01; 189(7):3759-66. Kwek SS, Dao V, Roy R, Hou Y, Alajajian D, Simko JP, Small EJ, Fong L. PMID: 22956585; PMCID: PMC3448828.
      View in: PubMed   Mentions: 42     Fields:    Translation:HumansAnimalsCellsCTClinical Trials
    204. Improved overall survival trends of men with newly diagnosed M1 prostate cancer: a SWOG phase III trial experience (S8494, S8894 and S9346). J Urol. 2012 Oct; 188(4):1164-9. Tangen CM, Hussain MH, Higano CS, Eisenberger MA, Small EJ, Wilding G, Donnelly BJ, Schelhammer PF, Crawford ED, Vogelzang NJ, Powell IJ, Thompson IM. PMID: 22921015; PMCID: PMC3481164.
      View in: PubMed   Mentions: 40     Fields:    Translation:Humans
    205. Re: interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer. J Natl Cancer Inst. 2012 Jul 18; 104(14):1107-9; author reply 1109-12. Kantoff PW, Higano CS, Small EJ, Whitmore JB, Frohlich MW, Schellhammer PF. PMID: 22825556.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    206. The future of cancer treatment: will it include immunotherapy? Cancer Cell. 2012 Jul 10; 22(1):7-8. Bluestone JA, Small EJ. PMID: 22789534.
      View in: PubMed   Mentions: 1     Fields:    
    207. Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. J Clin Oncol. 2012 May 01; 30(13):1534-40. Kelly WK, Halabi S, Carducci M, George D, Mahoney JF, Stadler WM, Morris M, Kantoff P, Monk JP, Kaplan E, Vogelzang NJ, Small EJ. PMID: 22454414; PMCID: PMC3383121.
      View in: PubMed   Mentions: 242     Fields:    Translation:HumansCTClinical Trials
    208. Efficacy of peripheral androgen blockade in prostate cancer patients with biochemical failure after definitive local therapy: results of Cancer and Leukemia Group B (CALGB) 9782. Cancer. 2012 Sep 01; 118(17):4139-47. Monk JP, Halabi S, Picus J, Hussain A, Philips G, Kaplan E, Ahles T, Gu L, Vogelzang N, Kelly WK, Small EJ, Cancer and Leukemia Group B. PMID: 22180287; PMCID: PMC5558439.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCTClinical Trials
    209. A phase II study of insulin-like growth factor receptor inhibition with nordihydroguaiaretic acid in men with non-metastatic hormone-sensitive prostate cancer. Oncol Rep. 2012 Jan; 27(1):3-9. Friedlander TW, Weinberg VK, Huang Y, Mi JT, Formaker CG, Small EJ, Harzstark AL, Lin AM, Fong L, Ryan CJ. PMID: 21971890.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCTClinical Trials
    210. Prostate cancer: evolution or revolution? J Clin Oncol. 2011 Sep 20; 29(27):3595-8. Small EJ, de Bono JS. PMID: 21859996.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    211. Combination external beam radiation and brachytherapy boost with androgen deprivation for treatment of intermediate-risk prostate cancer: long-term results of CALGB 99809. Cancer. 2011 Dec 15; 117(24):5579-88. Hurwitz MD, Halabi S, Archer L, McGinnis LS, Kuettel MR, DiBiase SJ, Small EJ. PMID: 22535500; PMCID: PMC3338200.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    212. The relationship between symptomatology and treatment selection in metastatic castrate-resistant prostate cancer. Clin Adv Hematol Oncol. 2011 Jul; 9(7 Suppl 13):1-15. Small EJ, Penson DF, Sartor O. PMID: 22361784.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    213. Phase II study of abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer displaying bone flare discordant with serologic response. Clin Cancer Res. 2011 Jul 15; 17(14):4854-61. Ryan CJ, Shah S, Efstathiou E, Smith MR, Taplin ME, Bubley GJ, Logothetis CJ, Kheoh T, Kilian C, Haqq CM, Molina A, Small EJ. PMID: 21632851; PMCID: PMC3657705.
      View in: PubMed   Mentions: 95     Fields:    Translation:HumansCTClinical Trials
    214. A phase 1 study of everolimus and sorafenib for metastatic clear cell renal cell carcinoma. Cancer. 2011 Sep 15; 117(18):4194-200. Harzstark AL, Small EJ, Weinberg VK, Sun J, Ryan CJ, Lin AM, Fong L, Brocks DR, Rosenberg JE. PMID: 21387258.
      View in: PubMed   Mentions: 27     Fields:    Translation:HumansCTClinical Trials
    215. Ixabepilone, mitoxantrone, and prednisone for metastatic castration-resistant prostate cancer after docetaxel-based therapy: a phase 2 study of the Department Of Defense Prostate Cancer Clinical Trials Consortium. Cancer. 2011 Jun 01; 117(11):2419-25. Harzstark AL, Rosenberg JE, Weinberg VK, Sharib J, Ryan CJ, Smith DC, Pagliaro LC, Beer TM, Liu G, Small EJ. PMID: 24048789.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    216. Bevacizumab and everolimus in renal cancer: a rational way forward. J Clin Oncol. 2010 Nov 20; 28(33):e692-3; author reply e694. Stadler WM, Phillips G, George DJ, Halabi S, Small E. PMID: 20940194.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    217. Effect of the somatostatin analog octreotide acetate on circulating insulin-like growth factor-1 and related peptides in patients with non-metastatic castration-resistant prostate cancer: results of a phase II study. Urol Oncol. 2012 Jul-Aug; 30(4):408-14. Friedlander TW, Weinberg VK, Small EJ, Sharib J, Harzstark AL, Lin AM, Fong L, Ryan CJ. PMID: 20884247.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCTClinical Trials
    218. A phase 2 study of estramustine, docetaxel, and bevacizumab in men with castrate-resistant prostate cancer: results from Cancer and Leukemia Group B Study 90006. Cancer. 2011 Feb 01; 117(3):526-33. Picus J, Halabi S, Kelly WK, Vogelzang NJ, Whang YE, Kaplan EB, Stadler WM, Small EJ, Cancer and Leukemia Group B. PMID: 20862750; PMCID: PMC3010428.
      View in: PubMed   Mentions: 31     Fields:    Translation:HumansCTClinical Trials
    219. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010 Jul 29; 363(5):411-22. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, Xu Y, Frohlich MW, Schellhammer PF, IMPACT Study Investigators. PMID: 20818862.
      View in: PubMed   Mentions: 2224     Fields:    Translation:HumansCellsCTClinical Trials
    220. Sipuleucel-T. Nat Rev Drug Discov. 2010 Jul; 9(7):513-4. Higano CS, Small EJ, Schellhammer P, Yasothan U, Gubernick S, Kirkpatrick P, Kantoff PW. PMID: 20592741.
      View in: PubMed   Mentions: 66     Fields:    Translation:HumansCells
    221. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol. 2010 May 01; 28(13):2137-43. Rini BI, Halabi S, Rosenberg JE, Stadler WM, Vaena DA, Archer L, Atkins JN, Picus J, Czaykowski P, Dutcher J, Small EJ. PMID: 20368558; PMCID: PMC2860433.
      View in: PubMed   Mentions: 291     Fields:    Translation:HumansCTClinical Trials
    222. Castrate-resistant prostate cancer: therapeutic strategies. Expert Opin Pharmacother. 2010 Apr; 11(6):937-45. Harzstark AL, Small EJ. PMID: 20307219.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    223. Cilengitide (EMD 121974, NSC 707544) in asymptomatic metastatic castration resistant prostate cancer patients: a randomized phase II trial by the prostate cancer clinical trials consortium. Invest New Drugs. 2011 Dec; 29(6):1432-40. Bradley DA, Daignault S, Ryan CJ, Dipaola RS, Cooney KA, Smith DC, Small E, Mathew P, Gross ME, Stein MN, Chen A, Pienta KJ, Escara-Wilke J, Doyle G, Al-Hawary M, Keller ET, Hussain M. PMID: 20336348; PMCID: PMC2917503.
      View in: PubMed   Mentions: 25     Fields:    Translation:HumansCellsCTClinical Trials
    224. Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. J Clin Oncol. 2010 Mar 20; 28(9):1489-95. Reid AH, Attard G, Danila DC, Oommen NB, Olmos D, Fong PC, Molife LR, Hunt J, Messiou C, Parker C, Dearnaley D, Swennenhuis JF, Terstappen LW, Lee G, Kheoh T, Molina A, Ryan CJ, Small E, Scher HI, de Bono JS. PMID: 20159823; PMCID: PMC2849770.
      View in: PubMed   Mentions: 164     Fields:    Translation:HumansCTClinical Trials
    225. Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. J Clin Oncol. 2010 Mar 20; 28(9):1481-8. Ryan CJ, Smith MR, Fong L, Rosenberg JE, Kantoff P, Raynaud F, Martins V, Lee G, Kheoh T, Kim J, Molina A, Small EJ. PMID: 20159824; PMCID: PMC2849769.
      View in: PubMed   Mentions: 153     Fields:    Translation:HumansCTClinical Trials
    226. Developing immunotherapy as legitimate therapy for patients with prostate cancer. J Clin Oncol. 2010 Mar 01; 28(7):1085-7. Small EJ, Fong L. PMID: 20100956.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    227. Emerging biological observations in prostate cancer. Expert Rev Anticancer Ther. 2010 Jan; 10(1):89-101. Shah S, Small E. PMID: 20014889.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansAnimalsCells
    228. Arsenic trioxide in recurrent urothelial cancer: a cancer and leukemia group B phase II trial (CALGB 99903). Clin Genitourin Cancer. 2009 Oct; 7(3):E66-70. Bajorin DF, Halabi S, Small E. PMID: 19815484.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    229. The mechanism of action of estrogen in castration-resistant prostate cancer: clues from hormone levels. Clin Genitourin Cancer. 2009 Oct; 7(3):E71-6. Aggarwal R, Weinberg V, Small EJ, Oh W, Rushakoff R, Ryan CJ. PMID: 19815485.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    230. A phase I study of a 2-day lapatinib chemosensitization pulse preceding nanoparticle albumin-bound Paclitaxel for advanced solid malignancies. Clin Cancer Res. 2009 Sep 01; 15(17):5569-75. Chien AJ, Illi JA, Ko AH, Korn WM, Fong L, Chen LM, Kashani-Sabet M, Ryan CJ, Rosenberg JE, Dubey S, Small EJ, Jahan TM, Hylton NM, Yeh BM, Huang Y, Koch KM, Moasser MM. PMID: 19706807; PMCID: PMC3029022.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansCTClinical Trials
    231. Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer. 2009 Aug 15; 115(16):3670-9. Higano CS, Schellhammer PF, Small EJ, Burch PA, Nemunaitis J, Yuh L, Provost N, Frohlich MW. PMID: 19536890.
      View in: PubMed   Mentions: 326     Fields:    Translation:HumansCTClinical Trials
    232. Progression-free survival as a predictor of overall survival in men with castrate-resistant prostate cancer. J Clin Oncol. 2009 Jun 10; 27(17):2766-71. Halabi S, Vogelzang NJ, Ou SS, Owzar K, Archer L, Small EJ. PMID: 19380448; PMCID: PMC2698015.
      View in: PubMed   Mentions: 40     Fields:    Translation:Humans
    233. Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916. J Clin Oncol. 2009 May 20; 27(15):2450-6. Hussain M, Goldman B, Tangen C, Higano CS, Petrylak DP, Wilding G, Akdas AM, Small EJ, Donnelly BJ, Sundram SK, Burch PA, Dipaola RS, Crawford ED. PMID: 19380444; PMCID: PMC2684851.
      View in: PubMed   Mentions: 73     Fields:    Translation:HumansCTClinical Trials
    234. Phase I study of ixabepilone, mitoxantrone, and prednisone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel-based therapy: a study of the department of defense prostate cancer clinical trials consortium. J Clin Oncol. 2009 Jun 10; 27(17):2772-8. Rosenberg JE, Ryan CJ, Weinberg VK, Smith DC, Hussain M, Beer TM, Ryan CW, Mathew P, Pagliaro LC, Harzstark AL, Sharib J, Small EJ. PMID: 19349545; PMCID: PMC2698016.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    235. Immunotherapeutics in development for prostate cancer. Oncologist. 2009 Apr; 14(4):391-8. Harzstark AL, Small EJ. PMID: 19342474.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCells
    236. A phase II trial of cisplatin (C), gemcitabine (G) and gefitinib for advanced urothelial tract carcinoma: results of Cancer and Leukemia Group B (CALGB) 90102. Ann Oncol. 2009 Jun; 20(6):1074-9. Philips GK, Halabi S, Sanford BL, Bajorin D, Small EJ, Cancer and Leukemia Group B. PMID: 19168670; PMCID: PMC2685451.
      View in: PubMed   Mentions: 39     Fields:    Translation:HumansCTClinical Trials
    237. Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF. Cancer Res. 2009 Jan 15; 69(2):609-15. Fong L, Kwek SS, O'Brien S, Kavanagh B, McNeel DG, Weinberg V, Lin AM, Rosenberg J, Ryan CJ, Rini BI, Small EJ. PMID: 19147575.
      View in: PubMed   Mentions: 125     Fields:    Translation:HumansCellsCTClinical Trials
    238. Department of Defense prostate cancer clinical trials consortium: a new instrument for prostate cancer clinical research. Clin Genitourin Cancer. 2009 Jan; 7(1):51-7. Morris MJ, Basch EM, Wilding G, Hussain M, Carducci MA, Higano C, Kantoff P, Oh WK, Small EJ, George D, Mathew P, Beer TM, Slovin SF, Ryan C, Logothetis C, Scher HI. PMID: 19213669; PMCID: PMC3394090.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    239. Bladder cancer. J Natl Compr Canc Netw. 2009 Jan; 7(1):8-39. Montie JE, Clark PE, Eisenberger MA, El-Galley R, Greenberg RE, Herr HW, Hudes GR, Kuban DA, Kuzel TM, Lange PH, Lele SM, Michalski J, Patterson A, Pohar KS, Richie JP, Sexton WJ, Shipley WU, Small EJ, Trump DL, Walther PJ, Wilson TG, National Comprehensive Cancer Network. PMID: 19176203.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    240. Multicenter phase 2 study of neoadjuvant paclitaxel, estramustine phosphate, and carboplatin plus androgen deprivation before radiation therapy in patients with unfavorable-risk localized prostate cancer: results of Cancer and Leukemia Group B 99811. Cancer. 2008 Dec 01; 113(11):3137-45. Kelly WK, Halabi S, Elfiky A, Ou SS, Bogart J, Zelefsky M, Small E, Cancer Leukemia Group B. PMID: 18989865.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    241. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol. 2008 Nov 20; 26(33):5422-8. Rini BI, Halabi S, Rosenberg JE, Stadler WM, Vaena DA, Ou SS, Archer L, Atkins JN, Picus J, Czaykowski P, Dutcher J, Small EJ. PMID: 18936475; PMCID: PMC2651074.
      View in: PubMed   Mentions: 336     Fields:    Translation:HumansCTClinical Trials
    242. Anti-cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment. J Clin Oncol. 2008 Nov 10; 26(32):5275-83. Fong L, Small EJ. PMID: 18838703.
      View in: PubMed   Mentions: 118     Fields:    Translation:HumansAnimals
    243. Treatment of biochemical recurrence of prostate cancer with granulocyte-macrophage colony-stimulating factor secreting, allogeneic, cellular immunotherapy. J Urol. 2008 Nov; 180(5):2011-7; discussion 2017-8. Urba WJ, Nemunaitis J, Marshall F, Smith DC, Hege KM, Ma J, Nguyen M, Small EJ. PMID: 18801509.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCTClinical Trials
    244. A phase II study of estramustine, docetaxel, and exisulind in patients with hormone- refractory prostate cancer: results of cancer and leukemia group B trial 90004. Clin Genitourin Cancer. 2008 Sep; 6(2):110-6. Dawson NA, Halabi S, Ou SS, Biggs DD, Kessinger A, Vogelzang N, Clamon GH, Nanus DM, Kelly WK, Small EJ, Cancer And Leukemia Group B. PMID: 18824434.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    245. Phase 1/2 dose-escalation study of a GM-CSF-secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancer. Cancer. 2008 Sep 01; 113(5):975-84. Higano CS, Corman JM, Smith DC, Centeno AS, Steidle CP, Gittleman M, Simons JW, Sacks N, Aimi J, Small EJ. PMID: 18646045.
      View in: PubMed   Mentions: 86     Fields:    Translation:HumansCellsCTClinical Trials
    246. von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma. J Urol. 2008 Sep; 180(3):860-5; discussion 865-6. Choueiri TK, Vaziri SA, Jaeger E, Elson P, Wood L, Bhalla IP, Small EJ, Weinberg V, Sein N, Simko J, Golshayan AR, Sercia L, Zhou M, Waldman FM, Rini BI, Bukowski RM, Ganapathi R. PMID: 18635227.
      View in: PubMed   Mentions: 86     Fields:    Translation:Humans
    247. CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion. Blood. 2008 Aug 15; 112(4):1175-83. Kavanagh B, O'Brien S, Lee D, Hou Y, Weinberg V, Rini B, Allison JP, Small EJ, Fong L. PMID: 18523152; PMCID: PMC2515138.
      View in: PubMed   Mentions: 120     Fields:    Translation:HumansCellsCTClinical Trials
    248. Pain predicts overall survival in men with metastatic castration-refractory prostate cancer. J Clin Oncol. 2008 May 20; 26(15):2544-9. Halabi S, Vogelzang NJ, Kornblith AB, Ou SS, Kantoff PW, Dawson NA, Small EJ. PMID: 18487572.
      View in: PubMed   Mentions: 79     Fields:    Translation:Humans
    249. Prostate cancer update: 2007. Curr Opin Oncol. 2008 May; 20(3):294-9. Lin AM, Small EJ. PMID: 18391629.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansPHPublic Health
    250. Combination external beam radiation and brachytherapy boost with androgen suppression for treatment of intermediate-risk prostate cancer: an initial report of CALGB 99809. Int J Radiat Oncol Biol Phys. 2008 Nov 01; 72(3):814-9. Hurwitz MD, Halabi S, Ou SS, McGinnis LS, Keuttel MR, Dibiase SJ, Small EJ. PMID: 18407435.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansPHPublic HealthCTClinical Trials
    251. Sipuleucel-T for the treatment of prostate cancer. Drugs Today (Barc). 2008 Apr; 44(4):271-8. Harzstark AL, Small EJ. PMID: 18536785.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    252. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol. 2008 Mar 01; 26(7):1148-59. Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, Eisenberger MA, Higano C, Bubley GJ, Dreicer R, Petrylak D, Kantoff P, Basch E, Kelly WK, Figg WD, Small EJ, Beer TM, Wilding G, Martin A, Hussain M, Prostate Cancer Clinical Trials Working Group. PMID: 18309951; PMCID: PMC4010133.
      View in: PubMed   Mentions: 927     Fields:    Translation:Humans
    253. p53 protein expression status and recurrence in men treated with radiation and androgen suppression therapy for higher-risk prostate cancer: a prospective phase II Cancer and Leukemia Group B Study (CALGB 9682). Urology. 2008 May; 71(5):933-7. D'Amico AV, Halabi S, Vollmer R, Loffredo M, McMahon E, Sanford B, Archer L, Vogelzang NJ, Small EJ, Kantoff PW, Cancer and Leukemia Group B. PMID: 18291508.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCTClinical Trials
    254. Phase II study of bortezomib in patients with previously treated advanced urothelial tract transitional cell carcinoma: CALGB 90207. Ann Oncol. 2008 May; 19(5):946-50. Rosenberg JE, Halabi S, Sanford BL, Himelstein AL, Atkins JN, Hohl RJ, Millard F, Bajorin DF, Small EJ, Cancer and Leukemia Group B. PMID: 18272914; PMCID: PMC5815560.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansCTClinical Trials
    255. A pilot dose-escalation study of the effects of nordihydroguareacetic acid on hormone and prostate specific antigen levels in patients with relapsed prostate cancer. BJU Int. 2008 Feb; 101(4):436-9. Ryan CJ, Harzstark AH, Rosenberg J, Lin A, Claros C, Goldfine ID, Kerner JF, Small EJ, Youngren JF. PMID: 18234062.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    256. Tumor volume changes on 1.5 tesla endorectal MRI during neoadjuvant androgen suppression therapy for higher-risk prostate cancer and recurrence in men treated using radiation therapy results of the phase II CALGB 9682 study. Int J Radiat Oncol Biol Phys. 2008 May 01; 71(1):9-15. D'Amico AV, Halabi S, Tempany C, Titelbaum D, Philips GK, Loffredo M, McMahon E, Sanford B, Vogelzang NJ, Small EJ, Cancer and Leukemia Group B. PMID: 18037582; PMCID: PMC2976647.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCTClinical Trials
    257. Phase II study of ketoconazole plus granulocyte-macrophage colony-stimulating factor for prostate cancer: effect of extent of disease on outcome. J Urol. 2007 Dec; 178(6):2372-6; discussion 2377. Ryan CJ, Weinberg V, Rosenberg J, Fong L, Lin A, Kim J, Small EJ. PMID: 17936834.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCTClinical Trials
    258. A phase II trial of cisplatin, fixed dose-rate gemcitabine and gefitinib for advanced urothelial tract carcinoma: results of the Cancer and Leukaemia Group B 90102. BJU Int. 2008 Jan; 101(1):20-5. Philips GK, Halabi S, Sanford BL, Bajorin D, Small EJ, Cancer and Leukaemia Group B. PMID: 17922873.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCTClinical Trials
    259. Androgen-response elements in hormone-refractory prostate cancer: implications for treatment development. Lancet Oncol. 2007 Oct; 8(10):933-9. Hsieh AC, Small EJ, Ryan CJ. PMID: 17913662.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCells
    260. Management of hormone refractory prostate cancer. Curr Opin Support Palliat Care. 2007 Oct; 1(3):187-91. Lin AM, Small EJ. PMID: 18685361.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    261. Inverse correlation between body mass index and clinical outcomes in men with advanced castration-recurrent prostate cancer. Cancer. 2007 Oct 01; 110(7):1478-84. Halabi S, Ou SS, Vogelzang NJ, Small EJ. PMID: 17665494.
      View in: PubMed   Mentions: 22     Fields:    Translation:Humans
    262. A phase II trial of gefitinib in patients with non-metastatic hormone-refractory prostate cancer. BJU Int. 2007 Oct; 100(4):765-9. Small EJ, Fontana J, Tannir N, DiPaola RS, Wilding G, Rubin M, Iacona RB, Kabbinavar FF. PMID: 17822457.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansCTClinical Trials
    263. Immunotherapy for prostate cancer using antigen-loaded antigen-presenting cells: APC8015 (Provenge). Expert Opin Biol Ther. 2007 Aug; 7(8):1275-80. Harzstark AL, Small EJ. PMID: 17696825.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansAnimalsCells
    264. Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients : randomized phase 2 study of ixabepilone or mitoxantrone and prednisone. Cancer. 2007 Aug 01; 110(3):556-63. Rosenberg JE, Weinberg VK, Kelly WK, Michaelson D, Hussain MH, Wilding G, Gross M, Hutcheon D, Small EJ. PMID: 17577218.
      View in: PubMed   Mentions: 42     Fields:    Translation:HumansCTClinical Trials
    265. Granulocyte macrophage colony-stimulating factor--secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer. Clin Cancer Res. 2007 Jul 01; 13(13):3883-91. Small EJ, Sacks N, Nemunaitis J, Urba WJ, Dula E, Centeno AS, Nelson WG, Ando D, Howard C, Borellini F, Nguyen M, Hege K, Simons JW. PMID: 17606721.
      View in: PubMed   Mentions: 100     Fields:    Translation:HumansCTClinical Trials
    266. A phase I trial of docetaxel/estramustine/imatinib in patients with hormone-refractory prostate cancer. Clin Genitourin Cancer. 2007 Jun; 5(5):323-8. Lin AM, Rini BI, Derynck MK, Weinberg V, Park M, Ryan CJ, Rosenberg JE, Bubley G, Small EJ. PMID: 17645829.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCTClinical Trials
    267. Immunotherapy for prostate cancer. Curr Oncol Rep. 2007 May; 9(3):226-33. Fong L, Small EJ. PMID: 17430695.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    268. Prostate cancer update: 2006. Curr Opin Oncol. 2007 May; 19(3):229-33. Lin AM, Small EJ. PMID: 17414641.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    269. Phase I dose escalation and pharmacokinetic study of AZD2171, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinase, in patients with hormone refractory prostate cancer (HRPC). Invest New Drugs. 2007 Oct; 25(5):445-51. Ryan CJ, Stadler WM, Roth B, Hutcheon D, Conry S, Puchalski T, Morris C, Small EJ. PMID: 17458505.
      View in: PubMed   Mentions: 33     Fields:    Translation:HumansCTClinical Trials
    270. Adrenal androgen levels as predictors of outcome in prostate cancer patients treated with ketoconazole plus antiandrogen withdrawal: results from a cancer and leukemia group B study. Clin Cancer Res. 2007 Apr 01; 13(7):2030-7. Ryan CJ, Halabi S, Ou SS, Vogelzang NJ, Kantoff P, Small EJ. PMID: 17404083.
      View in: PubMed   Mentions: 36     Fields:    Translation:HumansCTClinical Trials
    271. A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer. Clin Cancer Res. 2007 Mar 15; 13(6):1810-5. Small EJ, Tchekmedyian NS, Rini BI, Fong L, Lowy I, Allison JP. PMID: 17363537.
      View in: PubMed   Mentions: 167     Fields:    Translation:HumansCTClinical Trials
    272. Evaluation and significance of circulating epithelial cells in patients with hormone-refractory prostate cancer. BJU Int. 2007 Mar; 99(3):519-24. Garcia JA, Rosenberg JE, Weinberg V, Scott J, Frohlich M, Park JW, Small EJ. PMID: 17407512.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCells
    273. Expression of insulin-like growth factor-1 receptor in local and metastatic prostate cancer. Urol Oncol. 2007 Mar-Apr; 25(2):134-40. Ryan CJ, Haqq CM, Simko J, Nonaka DF, Chan JM, Weinberg V, Small EJ, Goldfine ID. PMID: 17349528.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansCells
    274. The impact of prior radical prostatectomy in men with metastatic castration recurrent prostate cancer: a pooled analysis of 9 Cancer and Leukemia Group B Trials. J Urol. 2007 Feb; 177(2):531-4. Halabi S, Vogelzang NJ, Ou SS, Small EJ. PMID: 17222627.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    275. Intermittent chemotherapy for metastatic hormone refractory prostate cancer. Crit Rev Oncol Hematol. 2007 Mar; 61(3):243-54. Lin AM, Ryan CJ, Small EJ. PMID: 17161610.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    276. The case for secondary hormonal therapies in the chemotherapy age. J Urol. 2006 Dec; 176(6 Pt 2):S66-71. Small EJ, Ryan CJ. PMID: 17084172.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    277. Telephone monitoring of distress in patients aged 65 years or older with advanced stage cancer: a cancer and leukemia group B study. Cancer. 2006 Dec 01; 107(11):2706-14. Kornblith AB, Dowell JM, Herndon JE, Engelman BJ, Bauer-Wu S, Small EJ, Morrison VA, Atkins J, Cohen HJ, Holland JC. PMID: 17078057.
      View in: PubMed   Mentions: 29     Fields:    Translation:Humans
    278. High risk biochemical relapse and the timing of androgen deprivation therapy. J Urol. 2006 Dec; 176(6 Pt 2):S61-5. Ryan CJ, Small EJ. PMID: 17084171.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    279. Bladder cancer. Clinical guidelines in oncology. J Natl Compr Canc Netw. 2006 Nov; 4(10):984-1014. Montie JE, Abrahams NA, Bahnson RR, Eisenberger MA, El-Galley R, Herr HW, Hudes GR, Kuzel TM, Lange PH, Patterson A, Pollack A, Richie JP, Sexton WJ, Shipley WU, Small EJ, Trump DL, Walther PJ, Wilson TG, National Comprehensive Cancer Network. PMID: 17112448.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    280. A phase II trial of imatinib mesylate in patients with biochemical relapse of prostate cancer after definitive local therapy. BJU Int. 2006 Oct; 98(4):763-9. Lin AM, Rini BI, Weinberg V, Fong K, Ryan CJ, Rosenberg JE, Fong L, Small EJ. PMID: 16796694.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansCTClinical Trials
    281. A phase II study of gemcitabine and capecitabine in metastatic renal cancer: a report of Cancer and Leukemia Group B protocol 90008. Cancer. 2006 Sep 15; 107(6):1273-9. Stadler WM, Halabi S, Rini B, Ernstoff MS, Davila E, Picus J, Barrier R, Small EJ, Cancer and Leukemia Group B. PMID: 16909426.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansCTClinical Trials
    282. Androgen deprivation therapy in locally advanced and metastatic prostate cancer. Minerva Urol Nefrol. 2006 Sep; 58(3):119-26. Ryan CJ, Small EJ. PMID: 17124482.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    283. Reduced incidence of bony metastasis at initial prostate cancer diagnosis: data from CaPSURE. Urol Oncol. 2006 Sep-Oct; 24(5):396-402. Ryan CJ, Elkin EP, Small EJ, Duchane J, Carroll P. PMID: 16962488.
      View in: PubMed   Mentions: 25     Fields:    Translation:Humans
    284. Immunotherapy for prostate cancer using prostatic acid phosphatase loaded antigen presenting cells. Urol Oncol. 2006 Sep-Oct; 24(5):434-41. Lin AM, Hershberg RM, Small EJ. PMID: 16962496.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    285. Sipuleucel-T (APC8015) for prostate cancer. Expert Rev Anticancer Ther. 2006 Sep; 6(9):1163-7. So-Rosillo R, Small EJ. PMID: 17020451.
      View in: PubMed   Mentions: 26     Fields:    Translation:Humans
    286. Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162). J Clin Oncol. 2006 Aug 20; 24(24):3984-90. Hussain M, Tangen CM, Higano C, Schelhammer PF, Faulkner J, Crawford ED, Wilding G, Akdas A, Small EJ, Donnelly B, MacVicar G, Raghavan D, Southwest Oncology Group Trial 9346 (INT-0162). PMID: 16921051.
      View in: PubMed   Mentions: 163     Fields:    Translation:Humans
    287. Clinical response to therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: impact of patient characteristics and Von Hippel-Lindau gene status. BJU Int. 2006 Oct; 98(4):756-62. Rini BI, Jaeger E, Weinberg V, Sein N, Chew K, Fong K, Simko J, Small EJ, Waldman FM. PMID: 16827904.
      View in: PubMed   Mentions: 37     Fields:    Translation:Humans
    288. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol. 2006 Jul 01; 24(19):3089-94. Small EJ, Schellhammer PF, Higano CS, Redfern CH, Nemunaitis JJ, Valone FH, Verjee SS, Jones LA, Hershberg RM. PMID: 16809734.
      View in: PubMed   Mentions: 408     Fields:    Translation:HumansCTClinical Trials
    289. Combination immunotherapy with prostatic acid phosphatase pulsed antigen-presenting cells (provenge) plus bevacizumab in patients with serologic progression of prostate cancer after definitive local therapy. Cancer. 2006 Jul 01; 107(1):67-74. Rini BI, Weinberg V, Fong L, Conry S, Hershberg RM, Small EJ. PMID: 16736512.
      View in: PubMed   Mentions: 32     Fields:    Translation:HumansCellsCTClinical Trials
    290. Clinical outcomes by age in men with hormone refractory prostate cancer: a pooled analysis of 8 Cancer and Leukemia Group B (CALGB) studies. J Urol. 2006 Jul; 176(1):81-6. Halabi S, Vogelzang NJ, Ou SS, Kelly WK, Small EJ. PMID: 16753374.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    291. Adoptive immunotherapy by allogeneic stem cell transplantation for metastatic renal cell carcinoma: a CALGB intergroup phase II study. Biol Blood Marrow Transplant. 2006 Jul; 12(7):778-85. Rini BI, Halabi S, Barrier R, Margolin KA, Avigan D, Logan T, Stadler WM, McCarthy PL, Linker CA, Small EJ, Cancer and Leukemia Group B, Eastern Cooperative Oncology Group, Southwestern Oncology Group. PMID: 16785067.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCTClinical Trials
    292. Clinical and immunological characteristics of patients with serologic progression of prostate cancer achieving long-term disease control with granulocyte-macrophage colony-stimulating factor. J Urol. 2006 Jun; 175(6):2087-91. Rini BI, Fong L, Weinberg V, Kavanaugh B, Small EJ. PMID: 16697809.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    293. Activities and accomplishments of the cancer and leukemia group B genitourinary committee. Clin Cancer Res. 2006 Jun 01; 12(11 Pt 2):3596s-600s. Small EJ, Halabi S, Kantoff P, D'Amico A, Stadler W, Kelley WK, Mohler J, Bajorin D, Vogelzang NJ. PMID: 16740791.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    294. A phase I trial of intravenous CG7870, a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer. Mol Ther. 2006 Jul; 14(1):107-17. Small EJ, Carducci MA, Burke JM, Rodriguez R, Fong L, van Ummersen L, Yu DC, Aimi J, Ando D, Working P, Kirn D, Wilding G. PMID: 16690359.
      View in: PubMed   Mentions: 93     Fields:    Translation:HumansCellsCTClinical Trials
    295. Results from a pilot Phase I trial of gefitinib combined with docetaxel and estramustine in patients with hormone-refractory prostate cancer. Cancer. 2006 May 01; 106(9):1917-24. Wilding G, Soulie P, Trump D, Das-Gupta A, Small E. PMID: 16568471.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCTClinical Trials
    296. Angiogenesis inhibition plus chemotherapy for metastatic hormone refractory prostate cancer: history and rationale. Urol Oncol. 2006 May-Jun; 24(3):250-3. Ryan CJ, Lin AM, Small EJ. PMID: 16678059.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    297. Immunotherapy for prostate cancer. Curr Urol Rep. 2006 May; 7(3):239-46. Fong L, Small EJ. PMID: 16630528.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    298. Clinical trials in patients with biochemically relapsed prostate cancer. BJU Int. 2006 May; 97(5):905-10. Lin AM, Rini BI, Small EJ. PMID: 16643469.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    299. Prostate cancer update: 2005. Curr Opin Oncol. 2006 May; 18(3):284-8. Ryan CJ, Small EJ. PMID: 16552242.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansPHPublic Health
    300. Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16. J Natl Cancer Inst. 2006 Apr 19; 98(8):516-21. Petrylak DP, Ankerst DP, Jiang CS, Tangen CM, Hussain MH, Lara PN, Jones JA, Taplin ME, Burch PA, Kohli M, Benson MC, Small EJ, Raghavan D, Crawford ED. PMID: 16622120.
      View in: PubMed   Mentions: 83     Fields:    Translation:Humans
    301. Prognostic significance of plasma scatter factor/hepatocyte growth factor levels in patients with metastatic hormone- refractory prostate cancer: results from cancer and leukemia group B 150005/9480. Clin Genitourin Cancer. 2006 Mar; 4(4):269-74. Humphrey PA, Halabi S, Picus J, Sanford B, Vogelzang NJ, Small EJ, Kantoff PW. PMID: 16729910.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    302. Maximal COX-2 immunostaining and clinical response to celecoxib and interferon alpha therapy in metastatic renal cell carcinoma. Cancer. 2006 Feb 01; 106(3):566-75. Rini BI, Weinberg V, Dunlap S, Elchinoff A, Yu N, Bok R, Simko J, Small EJ. PMID: 16369983.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansCTClinical Trials
    303. A retrospective evaluation of second-line chemotherapy response in hormone-refractory prostate carcinoma: second line taxane-based therapy after first-line epothilone-B analog ixabepilone (BMS-247550) therapy. Cancer. 2006 Jan 01; 106(1):58-62. Rosenberg JE, Galsky MD, Rohs NC, Weinberg VK, Oh WK, Kelly WK, Small EJ. PMID: 16329138.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    304. Predictors of prostate cancer tissue acquisition by an undirected core bone marrow biopsy in metastatic castration-resistant prostate cancer--a Cancer and Leukemia Group B study. Clin Cancer Res. 2005 Nov 15; 11(22):8109-13. Ross RW, Halabi S, Ou SS, Rajeshkumar BR, Woda BA, Vogelzang NJ, Small EJ, Taplin ME, Kantoff PW, Cancer and Leukemia Group B. PMID: 16299243.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    305. Prostate cancer immunology: biology, therapeutics, and challenges. J Clin Oncol. 2005 Nov 10; 23(32):8262-9. Webster WS, Small EJ, Rini BI, Kwon ED. PMID: 16278482.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    306. Early versus delayed androgen deprivation for prostate cancer: new fuel for an old debate. J Clin Oncol. 2005 Nov 10; 23(32):8225-31. Ryan CJ, Small EJ. PMID: 16278477.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    307. Phase II trial of carboplatin and paclitaxel in cisplatin-pretreated advanced transitional cell carcinoma: a Southwest Oncology Group study. Cancer. 2005 Oct 15; 104(8):1627-32. Vaishampayan UN, Faulkner JR, Small EJ, Redman BG, Keiser WL, Petrylak DP, Crawford ED. PMID: 16138364.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansCTClinical Trials
    308. Prior estrogen therapy as a predictor of response to subsequent estramustine-based chemotherapy in patients with androgen-independent prostate cancer. Clin Prostate Cancer. 2005 Sep; 4(2):113-7. Garcia JA, Weinberg V, Small EJ. PMID: 16197612.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    309. Prognostic significance of plasma chromogranin a levels in patients with hormone-refractory prostate cancer treated in Cancer and Leukemia Group B 9480 study. Urology. 2005 Aug; 66(2):386-91. Taplin ME, George DJ, Halabi S, Sanford B, Febbo PG, Hennessy KT, Mihos CG, Vogelzang NJ, Small EJ, Kantoff PW. PMID: 16098367.
      View in: PubMed   Mentions: 25     Fields:    Translation:Humans
    310. Prognostic significance of baseline reverse transcriptase-PCR for prostate-specific antigen in men with hormone-refractory prostate cancer treated with chemotherapy. Clin Cancer Res. 2005 Jul 15; 11(14):5195-8. Ross RW, Manola J, Hennessy K, Galsky M, Scher H, Small E, Kelly WK, Kantoff PW. PMID: 16033836.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    311. Update on chemotherapy for advanced bladder cancer. J Urol. 2005 Jul; 174(1):14-20. Rosenberg JE, Carroll PR, Small EJ. PMID: 15947569.
      View in: PubMed   Mentions: 47     Fields:    Translation:Humans
    312. Successful implementation of the randomized discontinuation trial design: an application to the study of the putative antiangiogenic agent carboxyaminoimidazole in renal cell carcinoma--CALGB 69901. J Clin Oncol. 2005 Jun 01; 23(16):3726-32. Stadler WM, Rosner G, Small E, Hollis D, Rini B, Zaentz SD, Mahoney J, Ratain MJ. PMID: 15923569.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansCTClinical Trials
    313. Antigen-presenting cells 8015 (Provenge) in patients with androgen-dependent, biochemically relapsed prostate cancer. Clin Prostate Cancer. 2005 Jun; 4(1):55-60. Beinart G, Rini BI, Weinberg V, Small EJ. PMID: 15992463.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCellsCTClinical Trials
    314. A phase II trial of R115777, an oral farnesyl transferase inhibitor, in patients with advanced urothelial tract transitional cell carcinoma. Cancer. 2005 May 15; 103(10):2035-41. Rosenberg JE, von der Maase H, Seigne JD, Mardiak J, Vaughn DJ, Moore M, Sahasrabudhe D, Palmer PA, Perez-Ruixo JJ, Small EJ. PMID: 15812833.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCTClinical Trials
    315. Progress in detection and treatment of prostate cancer. Curr Opin Oncol. 2005 May; 17(3):257-60. Ryan CJ, Small EJ. PMID: 15818171.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    316. Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer. J Clin Oncol. 2005 May 01; 23(13):2918-25. Smith MR, Kabbinavar F, Saad F, Hussain A, Gittelman MC, Bilhartz DL, Wynne C, Murray R, Zinner NR, Schulman C, Linnartz R, Zheng M, Goessl C, Hei YJ, Small EJ, Cook R, Higano CS. PMID: 15860850.
      View in: PubMed   Mentions: 167     Fields:    Translation:HumansCTClinical Trials
    317. Secondary hormonal manipulations in prostate cancer. Curr Oncol Rep. 2005 May; 7(3):228-33. Ryan CJ, Small EJ. PMID: 15847715.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    318. Elevated body mass index predicts for longer overall survival duration in men with metastatic hormone-refractory prostate cancer. J Clin Oncol. 2005 Apr 01; 23(10):2434-5; author reply 2435. Halabi S, Small EJ, Vogelzang NJ. PMID: 15800342.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    319. High-dose etoposide, thiotepa, and dose-adjusted carboplatin (TVCa) with autologous hematopoietic stem cell rescue as treatment of relapsed or refractory germ cell cancer. Am J Clin Oncol. 2005 Apr; 28(2):130-7. Chaudhary UB, Damon LE, Rugo HS, Linker CA, Navarro W, Small EJ. PMID: 15803005.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    320. Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer. J Clin Oncol. 2005 Mar 01; 23(7):1439-46. Galsky MD, Small EJ, Oh WK, Chen I, Smith DC, Colevas AD, Martone L, Curley T, Delacruz A, Scher HI, Kelly WK. PMID: 15735119.
      View in: PubMed   Mentions: 43     Fields:    Translation:HumansCTClinical Trials
    321. Lifestyle correlates of health perception and treatment satisfaction in a clinical cohort of men with prostate cancer. Clin Prostate Cancer. 2005 Mar; 3(4):239-45. Sheriff SK, Shohara RA, Dumican SB, Small EJ, Carroll PR, Chan JM. PMID: 15882480.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    322. The prognostic significance of plasma interleukin-6 levels in patients with metastatic hormone-refractory prostate cancer: results from cancer and leukemia group B 9480. Clin Cancer Res. 2005 Mar 01; 11(5):1815-20. George DJ, Halabi S, Shepard TF, Sanford B, Vogelzang NJ, Small EJ, Kantoff PW. PMID: 15756004.
      View in: PubMed   Mentions: 70     Fields:    Translation:Humans
    323. A phase I trial of fixed dose rate gemcitabine and capecitabine in metastatic renal cell carcinoma. Cancer. 2005 Feb 01; 103(3):553-8. Rini BI, Weinberg V, Small EJ. PMID: 15612026.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCTClinical Trials
    324. Kinetics of development and characteristics of antibodies induced in cancer patients against yeast expressed rDNA derived granulocyte macrophage colony stimulating factor (GM-CSF). Cytokine. 2005 Jan 21; 29(2):56-66. Rini B, Wadhwa M, Bird C, Small E, Gaines-Das R, Thorpe R. PMID: 15598439.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansAnimals
    325. Bladder cancer. Clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2005 Jan; 3(1):4-5, 19-34. Montie JE, Bahnson RR, Cohen SM, Drucker B, Eisenberger MA, El-Galley R, Herr HW, Hudes GR, Kuzel TM, Lange PH, Patterson A, Pollack A, Richie JP, Seigne J, Shipley WU, Small EJ, Trump DL, Walther PJ, Wilson TG, National Comprehensive Cancer Network. PMID: 19813320.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    326. Quality of life impact of three different doses of suramin in patients with metastatic hormone-refractory prostate carcinoma: results of Intergroup O159/Cancer and Leukemia Group B 9480. Cancer. 2004 Nov 15; 101(10):2202-8. Ahles TA, Herndon JE, Small EJ, Vogelzang NJ, Kornblith AB, Ratain MJ, Stadler W, Palchak D, Marshall ME, Wilding G, Petrylak D, Holland JC, Cancer and Leukemia Group B. PMID: 15484217.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCTClinical Trials
    327. Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma. J Clin Oncol. 2005 Feb 10; 23(5):1028-43. Rini BI, Small EJ. PMID: 15534359.
      View in: PubMed   Mentions: 108     Fields:    Translation:Humans
    328. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004 Oct 07; 351(15):1513-20. Petrylak DP, Tangen CM, Hussain MH, Lara PN, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, Benson MC, Small EJ, Raghavan D, Crawford ED. PMID: 15470214.
      View in: PubMed   Mentions: 1217     Fields:    Translation:HumansCTClinical Trials
    329. Rosiglitazone versus placebo for men with prostate carcinoma and a rising serum prostate-specific antigen level after radical prostatectomy and/or radiation therapy. Cancer. 2004 Oct 01; 101(7):1569-74. Smith MR, Manola J, Kaufman DS, George D, Oh WK, Mueller E, Slovin S, Spiegelman B, Small E, Kantoff PW. PMID: 15468186.
      View in: PubMed   Mentions: 54     Fields:    Translation:HumansCTClinical Trials
    330. Second-line chemotherapy for hormone-refractory prostate cancer: has the time come? Clin Prostate Cancer. 2004 Sep; 3(2):122-4. Rosenberg JE, Small EJ. PMID: 15479496.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    331. 9-Nitrocamptothecin as second line chemotherapy for men with progressive, metastatic, hormone refractory prostate cancer: Results of the CALGB 99901. Urol Oncol. 2004 Sep-Oct; 22(5):398-403. Amin A, Halabi S, Gelmann EP, Stadler W, Vogelzang N, Small E. PMID: 15464920.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    332. Prospective, multicenter, randomized phase II trial of the herbal supplement, PC-SPES, and diethylstilbestrol in patients with androgen-independent prostate cancer. J Clin Oncol. 2004 Sep 15; 22(18):3705-12. Oh WK, Kantoff PW, Weinberg V, Jones G, Rini BI, Derynck MK, Bok R, Smith MR, Bubley GJ, Rosen RT, DiPaola RS, Small EJ. PMID: 15289492.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansPHPublic HealthCTClinical Trials
    333. Impact of race on survival in men with metastatic hormone-refractory prostate cancer. Urology. 2004 Aug; 64(2):212-7. Halabi S, Small EJ, Vogelzang NJ, Barrier RC, George SL, Gilligan TD. PMID: 15302462.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    334. Time to disease progression to evaluate a novel protein kinase C inhibitor, UCN-01, in renal cell carcinoma. Cancer. 2004 Jul 01; 101(1):90-5. Rini BI, Weinberg V, Shaw V, Scott J, Bok R, Park JW, Small EJ. PMID: 15221993.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCellsCTClinical Trials
    335. Monoclonal antibody therapy for prostate cancer: finally a reality? J Clin Oncol. 2004 Jul 01; 22(13):2515-6. Small EJ. PMID: 15173211.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    336. Practice and progress in kidney cancer: methodology for novel drug development. J Urol. 2004 Jun; 171(6 Pt 1):2115-21. Rini BI, Weinberg V, Small EJ. PMID: 15126769.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    337. Advances in prostate cancer. Curr Opin Oncol. 2004 May; 16(3):242-6. Ryan CJ, Small EJ. PMID: 15069320.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansPHPublic Health
    338. The selection of hormonal therapy in prostate cancer: who, when, and for how long? J Natl Compr Canc Netw. 2004 May; 2(3):261-8. Ryan CJ, Small EJ. PMID: 19795609.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    339. Cancer and Leukemia Group B 90206: A randomized phase III trial of interferon-alpha or interferon-alpha plus anti-vascular endothelial growth factor antibody (bevacizumab) in metastatic renal cell carcinoma. Clin Cancer Res. 2004 Apr 15; 10(8):2584-6. Rini BI, Halabi S, Taylor J, Small EJ, Schilsky RL, Cancer and Leukemia Group B. PMID: 15102658.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansCTClinical Trials
    340. Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583). J Clin Oncol. 2004 Mar 15; 22(6):1025-33. Small EJ, Halabi S, Dawson NA, Stadler WM, Rini BI, Picus J, Gable P, Torti FM, Kaplan E, Vogelzang NJ. PMID: 15020604.
      View in: PubMed   Mentions: 165     Fields:    Translation:HumansCTClinical Trials
    341. Safety and biological activity of repeated doses of recombinant human Flt3 ligand in patients with bone scan-negative hormone-refractory prostate cancer. Clin Cancer Res. 2004 Feb 15; 10(4):1219-25. Higano CS, Vogelzang NJ, Sosman JA, Feng A, Caron D, Small EJ. PMID: 14977818.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCellsCTClinical Trials
    342. Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol. 2004 Feb 01; 22(3):537-56. Scher HI, Eisenberger M, D'Amico AV, Halabi S, Small EJ, Morris M, Kattan MW, Roach M, Kantoff P, Pienta KJ, Carducci MA, Agus D, Slovin SF, Heller G, Kelly WK, Lange PH, Petrylak D, Berg W, Higano C, Wilding G, Moul JW, Partin AN, Logothetis C, Soule HR. PMID: 14752077.
      View in: PubMed   Mentions: 61     Fields:    Translation:Humans
    343. Role of secondary hormonal therapy in the management of recurrent prostate cancer. Urology. 2003 Dec 29; 62 Suppl 1:87-94. Ryan CJ, Small EJ. PMID: 14747046.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    344. Cancer and Leukemia Group B (CALGB) 90203: a randomized phase 3 study of radical prostatectomy alone versus estramustine and docetaxel before radical prostatectomy for patients with high-risk localized disease. Urology. 2003 Dec 29; 62 Suppl 1:55-62. Eastham JA, Kelly WK, Grossfeld GD, Small EJ, Cancer and Leukemia Group B. PMID: 14747042.
      View in: PubMed   Mentions: 33     Fields:    Translation:HumansCTClinical Trials
    345. A phase II study of estramustine, docetaxel, and carboplatin with granulocyte-colony-stimulating factor support in patients with hormone-refractory prostate carcinoma: Cancer and Leukemia Group B 99813. Cancer. 2003 Dec 15; 98(12):2592-8. Oh WK, Halabi S, Kelly WK, Werner C, Godley PA, Vogelzang NJ, Small EJ, Cancer and Leukemia Group B 99813. PMID: 14669278.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansCTClinical Trials
    346. The evolving role of androgen deprivation therapy in the management of prostate cancer. Minerva Urol Nefrol. 2003 Dec; 55(4):219-38. Cooperberg MR, Small EJ, D'Amico A, Carroll PR. PMID: 14765015.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    347. Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer. J Clin Oncol. 2003 Dec 01; 21(23):4277-84. Small EJ, Smith MR, Seaman JJ, Petrone S, Kowalski MO. PMID: 14581438.
      View in: PubMed   Mentions: 83     Fields:    Translation:HumansCTClinical Trials
    348. Immunotherapy for prostate cancer. Semin Oncol. 2003 Oct; 30(5):649-58. Fong L, Small EJ. PMID: 14571412.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCells
    349. Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663. J Clin Oncol. 2003 Jul 15; 21(14):2673-8. Taplin ME, Rajeshkumar B, Halabi S, Werner CP, Woda BA, Picus J, Stadler W, Hayes DF, Kantoff PW, Vogelzang NJ, Small EJ, Cancer and Leukemia Group B Study 9663. PMID: 12860943.
      View in: PubMed   Mentions: 110     Fields:    Translation:HumansCellsCTClinical Trials
    350. The potential for prostate cancer immunotherapy. Crit Rev Oncol Hematol. 2003 Jun 27; 46 Suppl:S117-25. Rini BI, Small EJ. PMID: 12850532.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    351. Improvements in quality of life and disease-related symptoms in phase I trials of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumors. Clin Cancer Res. 2003 Jun; 9(6):2040-8. LoRusso PM, Herbst RS, Rischin D, Ranson M, Calvert H, Raymond E, Kieback D, Kaye S, Gianni L, Harris A, Bjork T, Maddox AM, Rothenberg ML, Small EJ, Rubin EH, Feyereislova A, Heyes A, Averbuch SD, Ochs J, Baselga J. PMID: 12796366.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    352. Prostate cancer update. Curr Opin Oncol. 2003 May; 15(3):217-21. Rosenberg J, Small EJ. PMID: 12778015.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    353. Overview of bladder cancer trials in the Cancer and Leukemia Group B. Cancer. 2003 Apr 15; 97(8 Suppl):2090-8. Small EJ, Halabi S, Dalbagni G, Pruthi R, Phillips G, Edelman M, Bajorin D, Cancer and Leukemia Group B. PMID: 12673701.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    354. Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol. 2003 Apr 01; 21(7):1232-7. Halabi S, Small EJ, Kantoff PW, Kattan MW, Kaplan EB, Dawson NA, Levine EG, Blumenstein BA, Vogelzang NJ. PMID: 12663709.
      View in: PubMed   Mentions: 257     Fields:    Translation:Humans
    355. Prognostic significance of reverse transcriptase polymerase chain reaction for prostate-specific antigen in metastatic prostate cancer: a nested study within CALGB 9583. J Clin Oncol. 2003 Feb 01; 21(3):490-5. Halabi S, Small EJ, Hayes DF, Vogelzang NJ, Kantoff PW. PMID: 12560440.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCells
    356. Prostate-specific antigen kinetics as a measure of the biologic effect of granulocyte-macrophage colony-stimulating factor in patients with serologic progression of prostate cancer. J Clin Oncol. 2003 Jan 01; 21(1):99-105. Rini BI, Weinberg V, Bok R, Small EJ. PMID: 12506177.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansCTClinical Trials
    357. Complementary and alternative therapies in prostate cancer. Semin Oncol. 2002 Dec; 29(6):575-84. Oh WK, Small EJ. PMID: 12516040.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    358. Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial. J Clin Oncol. 2002 Sep 15; 20(18):3815-25. Herbst RS, Maddox AM, Rothenberg ML, Small EJ, Rubin EH, Baselga J, Rojo F, Hong WK, Swaisland H, Averbuch SD, Ochs J, LoRusso PM. PMID: 12228201.
      View in: PubMed   Mentions: 106     Fields:    Translation:HumansCTClinical Trials
    359. Randomized study of three different doses of suramin administered with a fixed dosing schedule in patients with advanced prostate cancer: results of intergroup 0159, cancer and leukemia group B 9480. J Clin Oncol. 2002 Aug 15; 20(16):3369-75. Small EJ, Halabi S, Ratain MJ, Rosner G, Stadler W, Palchak D, Marshall E, Rago R, Hars V, Wilding G, Petrylak D, Vogelzang NJ. PMID: 12177096.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCTClinical Trials
    360. Low dose ketoconazole with replacement doses of hydrocortisone in patients with progressive androgen independent prostate cancer. J Urol. 2002 Aug; 168(2):542-5. Harris KA, Weinberg V, Bok RA, Kakefuda M, Small EJ. PMID: 12131305.
      View in: PubMed   Mentions: 21     Fields:    Translation:Humans
    361. Liposomal doxorubicin for the treatment of hormone-refractory prostate cancer. Clin Prostate Cancer. 2002 Jun; 1(1):37-41. Harris KA, Harney E, Small EJ. PMID: 15046711.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCTClinical Trials
    362. Prostate cancer update. Curr Opin Oncol. 2002 May; 14(3):286-91. Rini BI, Small EJ. PMID: 11981273.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    363. PC-SPES and prostate cancer. Urol Clin North Am. 2002 Feb; 29(1):59-66, viii. Oh WK, Small EJ. PMID: 12109356.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    364. Androgen deprivation therapy for patients with clinically localized (stages T1 to T3) prostate cancer and for patients with biochemical recurrence after radical prostatectomy. Urology. 2001 Aug; 58(2 Suppl 1):56-64. Grossfeld GD, Small EJ, Lubeck DP, Latini D, Broering JM, Carroll PR. PMID: 11502450.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    365. Secondary hormonal manipulation of prostate cancer. Curr Urol Rep. 2001 Jun; 2(3):224-30. Harris KA, Small EJ. PMID: 12084269.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    366. Vascular endothelial growth factor and basic fibroblast growth factor urine levels as predictors of outcome in hormone-refractory prostate cancer patients: a cancer and leukemia group B study. Cancer Res. 2001 Mar 15; 61(6):2533-6. Bok RA, Halabi S, Fei DT, Rodriquez CR, Hayes DF, Vogelzang NJ, Kantoff P, Shuman MA, Small EJ. PMID: 11289126.
      View in: PubMed   Mentions: 45     Fields:    Translation:Humans
    367. Hormonal treatment for prostate cancer. Expert Opin Investig Drugs. 2001 Mar; 10(3):493-510. Harris KA, Small EJ. PMID: 11227048.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansAnimals
    368. Serum prostate-specific antigen decline as a marker of clinical outcome in hormone-refractory prostate cancer patients: association with progression-free survival, pain end points, and survival. J Clin Oncol. 2001 Mar 01; 19(5):1304-11. Small EJ, McMillan A, Meyer M, Chen L, Slichenmyer WJ, Lenehan PF, Eisenberger M. PMID: 11230472.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCTClinical Trials
    369. Docetaxel in prostate cancer. Anticancer Drugs. 2001 Feb; 12 Suppl 1:S17-20. Small EJ. PMID: 11340899.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    370. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J Clin Oncol. 2000 Dec 01; 18(23):3894-903. Small EJ, Fratesi P, Reese DM, Strang G, Laus R, Peshwa MV, Valone FH. PMID: 11099318.
      View in: PubMed   Mentions: 162     Fields:    Translation:HumansCellsCTClinical Trials
    371. Prospective trial of the herbal supplement PC-SPES in patients with progressive prostate cancer. J Clin Oncol. 2000 Nov 01; 18(21):3595-603. Small EJ, Frohlich MW, Bok R, Shinohara K, Grossfeld G, Rozenblat Z, Kelly WK, Corry M, Reese DM. PMID: 11054432.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansCTClinical Trials
    372. Southwest Oncology Group Study of paclitaxel and carboplatin for advanced transitional-cell carcinoma: the importance of survival as a clinical trial end point. J Clin Oncol. 2000 Jul; 18(13):2537-44. Small EJ, Lew D, Redman BG, Petrylak DP, Hammond N, Gross HM, Eastham JA, Crawford ED. PMID: 10893284.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCTClinical Trials
    373. Management of a positive surgical margin after radical prostatectomy: decision analysis. J Urol. 2000 Jul; 164(1):93-9; discussion 100. Grossfeld GD, Tigrani VS, Nudell D, Roach M, Weinberg VK, Presti JC, Small EJ, Carroll PR. PMID: 10840431.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    374. An update on prostate cancer research. Curr Opin Oncol. 2000 May; 12(3):265-72. Small EJ, Reese DM. PMID: 10841200.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    375. A phase II pilot study of KW-2189 in patients with advanced renal cell carcinoma. Invest New Drugs. 2000 May; 18(2):193-7. Small EJ, Figlin R, Petrylak D, Vaughn DJ, Sartor O, Horak I, Pincus R, Kremer A, Bowden C. PMID: 10857997.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    376. Suramin therapy for patients with symptomatic hormone-refractory prostate cancer: results of a randomized phase III trial comparing suramin plus hydrocortisone to placebo plus hydrocortisone. J Clin Oncol. 2000 Apr; 18(7):1440-50. Small EJ, Meyer M, Marshall ME, Reyno LM, Meyers FJ, Natale RB, Lenehan PF, Chen L, Slichenmyer WJ, Eisenberger M. PMID: 10735891.
      View in: PubMed   Mentions: 33     Fields:    Translation:HumansCTClinical Trials
    377. Infusional floxuridine-based therapy for patients with metastatic renal cell carcinoma. Cancer. 2000 Mar 15; 88(6):1310-6. Reese DM, Corry M, Small EJ. PMID: 10717611.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    378. New treatment strategies in advanced prostate cancer. Radiol Clin North Am. 2000 Jan; 38(1):203-11, ix-x. Small EJ, Reese DM. PMID: 10664673.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    379. Potential role of nephrectomy in the treatment of metastatic renal cell carcinoma: a retrospective analysis. Urology. 2000 Jan; 55(1):36-40. Tigrani VS, Reese DM, Small EJ, Presti JC, Carroll PR. PMID: 10654891.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    380. Outpatient combination chemoimmunotherapy for patients with metastatic melanoma. Results of a phase I/II trial. Cancer. 1999 Nov 15; 86(10):2160-5. Kashani-Sabet M, Sagebiel RW, Collins HE, Glassberg AB, Allen RE, Leong SP, Small EJ. PMID: 10570447.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    381. Hormone-refractory prostate cancer: an evolving standard of care. Semin Oncol. 1999 Oct; 26(5 Suppl 17):61-7. Small EJ, Reese DM, Vogelzang NJ. PMID: 10604272.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    382. Therapy of advanced prostate cancer with granulocyte macrophage colony-stimulating factor. Clin Cancer Res. 1999 Jul; 5(7):1738-44. Small EJ, Reese DM, Um B, Whisenant S, Dixon SC, Figg WD. PMID: 10430077.
      View in: PubMed   Mentions: 44     Fields:    Translation:HumansCTClinical Trials
    383. Advances in prostate cancer. Curr Opin Oncol. 1999 May; 11(3):226-35. Small EJ. PMID: 10328599.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansPHPublic Health
    384. The treatment of advanced prostate cancer with ketoconazole: safety issues. Drug Saf. 1999 May; 20(5):451-8. Bok RA, Small EJ. PMID: 10348095.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansAnimals
    385. Secondary hormonal manipulations in hormone refractory prostate cancer. Urol Clin North Am. 1999 May; 26(2):311-21, viii. Reese DM, Small EJ. PMID: 10361554.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    386. Diffuse retroperitoneal amyloidosis due to renal cell carcinoma. Br J Radiol. 1999 Apr; 72(856):412-3. Coakley FV, Hricak H, Presti JC, Small EJ. PMID: 10474508.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    387. Stage II nonseminomatous testis cancer: the roles of primary and adjuvant chemotherapy. Urol Clin North Am. 1998 Aug; 25(3):451-9. Frohlich MW, Small EJ. PMID: 9728214.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    388. Long-term side effects of treatment for testis cancer. Urol Clin North Am. 1998 Aug; 25(3):503-15. Grossfeld GD, Small EJ. PMID: 9728220.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    389. Prostate cancer, Incidence, management and outcomes. Drugs Aging. 1998 Jul; 13(1):71-81. Small EJ. PMID: 9679210.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    390. Update on the diagnosis and treatment of prostate cancer. Curr Opin Oncol. 1998 May; 10(3):244-52. Small EJ. PMID: 9619361.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansPHPublic Health
    391. The treatment of metastatic renal cell carcinoma patients with recombinant human gamma interferon. Cancer J Sci Am. 1998 May-Jun; 4(3):162-7. Small EJ, Weiss GR, Malik UK, Walther PJ, Johnson D, Wilding G, Kuzel T, Bajamonde A, Paton V. PMID: 9612597.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    392. Intermittent androgen deprivation for clinically localized prostate cancer: initial experience. Urology. 1998 Jan; 51(1):137-44. Grossfeld GD, Small EJ, Carroll PR. PMID: 9457309.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCTClinical Trials
    393. Pyrazoloacridine for the treatment of hormone-refractory prostate cancer. Cancer Invest. 1998; 16(7):456-61. Small EJ, Fippin LJ, Whisenant SP. PMID: 9774952.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    394. Simultaneous antiandrogen withdrawal and treatment with ketoconazole and hydrocortisone in patients with advanced prostate carcinoma. Cancer. 1997 Nov 01; 80(9):1755-9. Small EJ, Baron A, Bok R. PMID: 9351544.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansCTClinical Trials
    395. Prostate cancer. Curr Opin Oncol. 1997 May; 9(3):277-86. Small EJ. PMID: 9229151.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansPHPublic Health
    396. Ketoconazole retains activity in advanced prostate cancer patients with progression despite flutamide withdrawal. J Urol. 1997 Apr; 157(4):1204-7. Small EJ, Baron AD, Fippin L, Apodaca D. PMID: 9120902.
      View in: PubMed   Mentions: 42     Fields:    Translation:HumansCTClinical Trials
    397. Focal therapy for prostate cancer 1996: maximizing outcome. Urology. 1997 Mar; 49(3A Suppl):84-94. Carroll PR, Presti JC, Small E, Roach M. PMID: 9123742.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    398. Second-line hormonal therapy for advanced prostate cancer: a shifting paradigm. J Clin Oncol. 1997 Jan; 15(1):382-8. Small EJ, Vogelzang NJ. PMID: 8996165.
      View in: PubMed   Mentions: 34     Fields:    Translation:Humans
    399. Cancer and Leukemia Group B trials for advanced prostate cancer. Semin Oncol. 1996 Dec; 23(6 Suppl 14):28-31. Small EJ, Dawson NA, Kantoff PW, Vogelzang NJ. PMID: 8996582.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    400. Radiotherapy for high grade clinically localized adenocarcinoma of the prostate. J Urol. 1996 Nov; 156(5):1719-23. Roach M, Meehan S, Kroll S, Weil M, Ryu J, Small EJ, Margolis LW, Presti J, Carroll PC, Phillips TL. PMID: 8863578.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    401. A carboplatin-based regimen for the treatment of patients with advanced transitional cell carcinoma of the urothelium. Cancer. 1996 Oct 15; 78(8):1775-80. Small EJ, Fippin LJ, Ernest ML, Carroll PR. PMID: 8859191.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    402. Genetic alterations in untreated metastases and androgen-independent prostate cancer detected by comparative genomic hybridization and allelotyping. Cancer Res. 1996 Jul 01; 56(13):3091-102. Cher ML, Bova GS, Moore DH, Small EJ, Carroll PR, Pin SS, Epstein JI, Isaacs WB, Jensen RH. PMID: 8674067.
      View in: PubMed   Mentions: 62     Fields:    Translation:HumansCells
    403. The antiandrogen withdrawal syndrome. Experience in a large cohort of unselected patients with advanced prostate cancer. Cancer. 1995 Oct 15; 76(8):1428-34. Small EJ, Srinivas S. PMID: 8620419.
      View in: PubMed   Mentions: 33     Fields:    Translation:Humans
    404. Malignant germ cell tumors in men infected with the human immunodeficiency virus: natural history and results of therapy. J Clin Oncol. 1995 Jun; 13(6):1391-7. Timmerman JM, Northfelt DW, Small EJ. PMID: 7538557.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    405. A phase I/II study of alternating constant rate infusion floxuridine with constant rate infusion vinblastine for the treatment of metastatic renal cell carcinoma. Cancer. 1994 Jun 01; 73(11):2803-7. Small EJ, Frye JW, Wilkinson MJ, Carroll PR, Ernest ML, Stagg RJ. PMID: 8194022.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    406. Prostate-specific antigen decline after casodex withdrawal: evidence for an antiandrogen withdrawal syndrome. Urology. 1994 Mar; 43(3):408-10. Small EJ, Carroll PR. PMID: 7510915.
      View in: PubMed   Mentions: 37     Fields:    Translation:Humans
    407. Nephrectomy for metastatic renal cell carcinoma: a component of systemic treatment regimens. J Surg Oncol. 1994 Jan; 55(1):7-13. Wolf JS, Aronson FR, Small EJ, Carroll PR. PMID: 8289458.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    408. Prostate cancer: who to screen, and what the results mean. Geriatrics. 1993 Dec; 48(12):28-30, 35-8. Small EJ. PMID: 7504646.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansPHPublic Health
    409. Gallium-avid thymic hyperplasia in an adult after chemotherapy for Hodgkin disease. Cancer. 1993 Aug 01; 72(3):905-8. Small EJ, Venook AP, Damon LE. PMID: 8334644.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    410. A phase II study of constant-infusion floxuridine for the treatment of metastatic renal cell carcinoma. Cancer. 1993 Jun 01; 71(11):3601-4. Wilkinson MJ, Frye JW, Small EJ, Venook AP, Carroll PR, Ernest ML, Stagg RJ. PMID: 8490909.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    With one click, see people who:

    Mentor Faculty

    Run Clinical Trials

    Work in Global Health Equity

    Offer Student Projects

    See more options in the Advanced Search tab

    Eric's Networks
    Concepts (766)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (174)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (59)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UCSF Profiles is managed by the UCSF Clinical and Translational Science Institute (CTSI), part of the Clinical and Translational Science Award program funded by the National Center for Advancing Translational Sciences (Grant Number UL1 TR000004) at the National Institutes of Health (NIH).

    We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use. This site is running Profiles RNS version UCSF-v3.1.0-3-g1ef1264b on PROFILES-PWEB04.

    Copyright © The Regents of the University of California.